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Studies on Antibacterial Activities of N-Thiolated β-Lactams and Their Polymeric 
Nanoparticles Against MRSA 
 
Jeung-Yeop Shim 
 
Abstract 
       Methicillin-resistant Staphylococcus Aureus (MRSA) is now the most challenging 
bacterial pathogen affecting patients in hospitals and in care centers, and has brought on 
the need to develop new drugs for MRSA. This thesis centers on studies of N-thiolated β-
lactams, a new family of potent antibacterial compounds that selectively inhibit the 
growth of methicillin-resistant Staphylococcus aureus (MRSA).  
       Chapter 1 describes MRSA in more detail. Chapter 2 outlines experiments on the 
effect of a fatty ester group (CO2R) on the C4-phenyl ring of N-methylthio β-lactams, 
expecting that attachment of long chain ester moieties might increase the hydrophobicity, 
and thus enhance the drug’s ability to penetrate through the cell membrane. However, the 
results indicate that antibacterial activity drops off rapidly when more than seven carbon 
atoms are in the chain. These results led to the idea about examining a β-lactam 
conjugated polymer as a possible pro-drug delivery method, which is the focus of 
Chapter 3.  
       To synthesize the initial drug-polymer candidate, microemulsion polymerization of 
an acrylate-substituted lactam was done in aqueous solution to form hydrophilic 
 xi
polymeric nanoparticles containing the highly water-insoluble solid antibiotic, N-
methylthio β-lactam. This method has advantages over the conventional emulsion 
polymerization methods because a solid co-monomer (β-lactam drug) can be utilized. 
       SEM studies show that these polymeric nanoparticles have a microspherical 
morphology with nano-sizes of 40-150 nm. The N-thiolated β-lactam containing 
nanoparticles display potent anti-MRSA activity at much lower drug amounts compared 
with free lactam drug, penicillin G or vancomycin. Although at this time the relationship 
between particle size and activity is not clear and the mode of action is unknown, the N-
thiolated β-lactam containing nanoparticles dramatically enhance bioactivity, possibly 
due to increased bioavailability of the antibiotic via endocytosis.  
       In chapter 4, Fluorescence-active emulsified nanoparticles containing naphthyl or 
anthracenyl side chains were also successfully prepared by microemulsion 
polymerization for possible use in fluorescence studies to determine if the drug enters the 
cell of MRSA through endocytosis, and where possible bioaccumulation site are located.   
 
 1
 
 
 
 
 
Chapter One 
 
Methicillin-resistant Staphylococcus aureus (MRSA) 
 
1.1  Introduction1,2,3,4
       Penicillin was the first antibiotic chemotherapeutic agent discovered and it was 
proven to be effective against specific bacteria when administered in the human body 
without destroying the body's own cells.  
       In 1928, Sir Alexander Fleming, professor of bacteriology at St. Mary's Hospital in 
London, was culturing Staphylococcus aureus. He noticed zones of growth inhibition 
where mold spores were growing. He named the mold Penicillium rubrum. It was 
determined that a secretion of the mold was effective against Gram-positive bacteria. In 
1940 Lord Howard Florey and Sir Ernst Chain successfully isolated the antimicrobial 
agent. It was determined to be an inhibitor of cell wall synthesis in gram-positive 
bacterial. Amidst the need for antibacterial agents in WW II, penicillin was isolated, 
purified and injected into experimental animals, where it was found to not only cure 
infections but also to possess low toxicity. This opened the age of antibiotic 
chemotherapy and promoted an intense search for similar antimicrobial agents of low 
toxicity that might prove useful in the treatment of infectious disease. Some time later, 
another mold was found which produced a bacteria-killing chemical, and the structure of 
the molecule was determined to be very similar to the penicillin molecule; this chemical 
and its cousins were called "cephalosporins" after the Cephalous mold from which they 
were derived (Fig. 1-1). Chemical changes have been made to the molecules over the 
years to improve their bacteria-fighting abilities and to help them overcome biochemical 
breakdown and "immunity" of resistant bacteria.  
N
S
O
CH3
CH3
HHN
O
OHO
N
S
O CH3
O
OHO
H
N
HO
H
O
O
H2N
O
Penicillin G Cephalosporin C  
                   Fig. 1-1 Chemical structure of penicillin G and cephalosporin C 
 
      The isolation of streptomycin, chloramphenicol and tetracycline soon followed, and 
by the 1950's, these and several other antibiotics were in clinical usage. 
       The bacterial cell has a cell wall similar to the outer layer of plant cells, but which is 
missing in human and animal cells. This wall must grow along with the cell, or the 
growing cell will eventually become too big for the wall and burst and die. Penicillins 
and cephalosporins kill bacteria by messing up the wall-building system. Since human 
cell do not have cell walls, and plants have a different wall-building system, neither 
human, nor animals, nor plants are affected by the penicillins. Some bacteria have 
changed the structure of their walls to prevent penicillin from entering, or have come up 
with ways to break down the penicillin structure. In the 1940's and 1950's, most bacteria 
could be killed by penicillin. Now, because no longer penicillins and cephalosporins have 
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been used so often there are many bacteria that no longer are killed by penicillin. 
Antibiotic resistance is a growing problem.  
 
1.2 Cell Wall Biosynthesis and Its Inhibition by Penicillins in Gram-positive   
Bacteria 
 
       The Gram-positive bacteria possess a thick cell wall composed of a cellulose-like 
polymer covalently interbound via short peptide units into layers (Fig. 1-2). This 
peptidoglycan substance is also found in Gram-negative cells, but is thinner and less 
fortified. Gram negative organisms also possess an outer membrane composed of 
lipoproteins, lipopolysaccharides, and phospholipids, which provide a natural barrier to 
the antimicrobial effects of penicillin.5        
       The polysaccharide portion of the peptidoglycan structure (fig. 1-5) is made of 
repeating units of N-acetylglucosamine (NAG) linked to N-acetylmuramic acid (NAG-
NAM) (Fig. 1-3). The peptide varies, but begins with L-Ala and ends with D-Ala. In the 
middle is a dibasic amino acid, diaminopimelate (DAP). The terminal Ala residues are 
used for glycan linkage; the DAP for interpeptide linkages. Different species of Gram-
positive bacteria possess different peptide units in the peptidoglycan cell wall.4,5 
 
 3
peptidoglycan plasma
membrane
 
Fig. 1-2 Gram-positive bacteria cell wall5
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                                   Fig. 1-3 Chemical structure of NAG-NAM1,2,5 
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Fig. 1-4 Cell wall biosynthesis of gram-positive bacteria1 
 
 
       The NAM part of the NAG-NAM monomer group provides the point of attachment 
for the peptide. The L-Ala residue is attached to the NAM. DAP provides a linkage to the 
D-Ala residue on an adjacent peptide, which continues to link distally with another layer 
of NAG-NAM (Fig. 1-4).  
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Fig. 1-5 Structure of peptidoglycan 
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       The transpeptide linkages are catalyzed by the enzyme glycopeptide transpeptidase 
(GPTase). A ser residue in the active site of GPTase is the target of penicillin attack. The 
anionic Ser residue attacks the carbonyl carbon of the  β-lactam ring since the 
conformation resembles the transition state of the normal GPTase substrate. This forms 
an indefinitely stable structure; thereby rendering the enzyme inactive. Without an active 
site, glycoprotein transpeptidation can not occur. Without transpeptidation, Gram-
positive cell walls can not be crosslinked. Therefore, those bacteria are easily killed (Fig. 
1-6).4,5
 
O
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RO
O
O
O
GPTase
 
Fig. 1-6  Inhibition of GTPase by penicillin 
 
1.3  Methicillin-Resistance 
       As early as the 1940s, bacteria began to develop resistance to penicillin. β-
Lactamases (or penicillinases) are enzymes produced by a bacterium which render 
penicillin useless by hydrolyzing the β-lactam ring. The β-lactamases catalytically 
disrupt the amide bond of penicillin, and other β-lactams, via the formation of a serine-
ester-linked acyl enzyme derivative. β-Lactams are structural analogs of the peptidyl-D-
alanyl-D-alanine terminal moiety of peptidoglycan cell wall precursors. Following β-
lactam binding, the β-lactam ring is opened by nucleophilic attack by the hydroxyl group 
of a serine residue. Acylation of the enzyme generates an acyl enzyme intermediate, 
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which undergoes subsequent hydrolysis to release the penicilloyl moiety and regenerating 
the active enzyme (Fig. 1-7).6,7,8,9
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Fig. 1-7 Hydrolysis of penicillin by β-lactamase 
 
       Strains of Staphylococcus aureus are resistant to methicillin, cloxacillin, 
flucloxacillin and to all the other β-lactam antibiotics, including all penicillins and 
cephalosporins. because of a change in the cell wall proteins. MRSA also has the ability 
to pick up other resistance mechanisms and may become resistant to all other anti-
staphylococcal drugs. With the widespread emergence of MRSA, glycopeptide 
antibiotics such as vancomycin or teicoplanin have been more frequently used in the 
clinical practice. Popular use of these agents has led to the onset of glycopeptide 
resistance at the end of the 20th century. In 1997, an isolate of S. aureus with reduced 
susceptibility to vancomycin (MIC ≥ 8 μg/mL) was first reported from Japan.10 Until 
2002, a total of 24 cases of Vancomycin-Intermediate Staphylococcus aureus (VISA) 
infections were reported from 11 countries in the world. In 2002, two strains of VRSA 
with high-level resistance to vancomycin (MIC ≥ 32 μg/mL) with van A gene from 
 7
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enterococci were reported in the U.S.11,12 It is anticipated that glycopeptide resistance will 
only continue to get worse within a few years. 
 
1.4 Trends in Resistance and Prospect for New Therapies  
       Natural selection is the driving force for the appearance of drug resistant strains. 
Once one strain of bacteria has become resistant, the resistance can be transferred 
between strains by several mechanisms involving exchange of genetic material. These 
mechanisms include conjugation, transduction, and transformation. The more an 
antibiotic is used, the greater the selective pressure of bacteria to become resistant, and 
the faster resistance spreads. The most evident example is penicillin. When penicillin was 
first discovered, it was believed to be a miracle drug and was used at any sign of infection. 
The emergence of resistant strains was almost immediate. MRSA is now the most 
challenging bacterial pathogen that currently affects patients in hospital and in the 
community. Infection caused by this important nosocomial bacterium has become a 
serious national and global problem. Fig. 1-813 indicates the development of MRSA in 
the recent years. Therefore, by studying the mechanisms by which strains become 
resistant, a better understanding of how to stop or slow down the emergence of resistant 
strains is possible. For example, for strains that produce β-lactamases, a β-lactamase 
inhibitor can be added in addition to the β-lactam drug to render the bacteria sensitive to 
the antibiotic. Development of drugs with a new mechanism of action are needed. 
Alternatively, new ways to deliver the antibiotic to the cell may help overcome resistance 
and minimize further expose of bacteria to the drug.  
        In next chapter, studies on a new family of potent antibacterial compounds, N-
thiolated β-lactams, that selectively inhibit the growth of Staphylococcus species are 
described. 
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Fig. 1-8  Proportion of S. aureus Nosocomial Infections Resistant to Oxacillin 
               Source: National Nocosomial Infections Surveillance (NNIS)  
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Chapter Two 
 
Influence of Fatty Ester Side Chains on the Antibacterial Activity of 
N-Methylthio β-Lactams 
 
2.1  Introduction 
       N-Thiolated β-lactams are a new family of potent antibacterial compounds that 
selectively inhibit the growth of Staphylococcus species. Members of this family of 
antibiotics show enhanced activity towards Staphylococcus microbes, including 
methicillin-resistant Staphylococcus aureus (MRSA), over other common bacterial 
genera.1 The initial lead compound I-A developed earlier in the Turos laboratory led to 
further investigations on the structure-activity studies patterns of these new antibacterial 
agents.2 Previous work found that certain lipophilic and electron withdrawing 
functionalities on the ring may be preferred. 
 
 11
 
 
                             
                                                                    I-A   
N
O S
O
CH3
CH3
12
3 4
 
The analogs of N-methylthio β-lactams, II-A, II-B, II-C, II-D, show potent 
activities against MRSA.3 These compounds are lipophilic and have the electron 
withdrawing functionality on the C4-phenyl group.  
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C4-Saturated/unsaturated side chain aryl analogs, III-A, III-B, III-C also have 
moderate antibacterial activities against MRSA.3 These compounds are lipophilic and 
even have no electron withdrawing substituent at C4.  
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       C4-Fluoro aryl analogs, IV-A, IV-B, IV-C, IV-D, also have strong antibacterial 
activities against MRSA.4  
 
 12
N
O S
O
CH3
CH3
F
N
O S
O
CH3
CH3
F
N
O S
O
CH3
CH3
F
F
F
F
N
O S
O
CH3
CH3
F
F
F
F
F
IV-B
IV-C IV-D
IV-A
 
      
       One of these compounds, ester analog II-B, has an ester group (CO2Me) on the C4-
phenyl ring of the lactam. This compound was found to be a reasonably potent analog 
among those we examined. The electron withdrawing ester group on the C4-phenyl group 
as well as the long alkyl chain of the ester group can possibly increase the hydrophobicity 
of N-methylthio β-lactam and thus may increase bioavailability by enhancing penetration 
through the cell membrane. Therefore, it is a good candidate for systematic investigation 
of the structure-activity relationship for N-methylthio β-lactams.                                                                
       In this study, the synthesis and evaluation of additional fatty ester analogs was 
carried out to address whether increasing the length or the degree of branching, and thus 
the hydrophobic character of the ester side chain, may alter the antibacterial properties.  
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2.2  Synthesis  
       A series of N-thiolated β-lactams 1, having a C4-fatty ester on the phenyl group was 
prepared.  
N
O S
R'O
CH3
CO2R
1  
       Scheme II-1 summarizes the synthesis of the first of these analogs, 3-methoxy- 
substituted C4-benzoate alkyl esters 7. 4-Carboxybenzaldehyde 2 was coupled with the 
appropriate alcohol using dicyclohexylcarbodiimide/dimethylaminopyridine 
(DCC/DMAP), followed by reaction with p-anisidine, to give alkyl ester imines 4. 
Staudinger coupling5-8 of methoxyacetyl chloride with the imine 4 gave N-aryl protected 
β-lactam alkyl ester 5. Dearylation of β-lactam 5 with ceric ammonium nitrate and 
methylthiolation with N-(methylthio)phthalimide affords C3-methoxy N-methylthio β-
lactam ester analogs 7.2  
       Ortho-substituted β-lactams 13 are also good candidates for the study of  biological 
activity. These compounds were prepared as shown in Scheme II-2. Even though ortho 
substituted methyl, ethyl, propyl and pentyl ester analogs were tried under the usual 
Staudinger coupling conditions, only ortho ethyl ester, gave results. In this case, cis and 
trans adducts were obtained. These adducts were taken on to the N-methylthio β-lactams 
13, which independently were tested for antibacterial activity by the Kirby-Bauer method 
of disc diffusion on agar plates.        
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       Scheme II-3 summarizes the synthesis of C3-acetoxy N-methylthio β-lactams 15. 
Staudinger coupling of acetoxyacetyl chloride with imine 4 gave C3-acetoxy N-aryl 
protected β-lactam 14. In some cases, both cis and trans adducts could be obtained from 
the Staudinger reaction. Dearylation of β-lactam 14 with ceric ammonium nitrate, 
followed by methylthiolation with N-(methylthio)phthalimide affords C3-acetoxy N-
methylthio β-lactams 15.  
       C3-Alkyl carbonate and methyl dithiocarbonate moieties also could be introduced to 
examine the effect of different functionalities and chain branching on bioactivity of the β-
lactam. Scheme II-4 summarizes the synthesis of C3-alkylcarbonate N-methylthio β-
lactam analogs 20. The C3-hydroxy β-lactam 17 could be easily obtained by cleavage of 
C3-acetoxy β-lactam 16 with methanolic KOH. The resulting free hydroxyl compound 17 
was reacted with alkyl orthochloroformate to give the C3-alkyl carbonate β-lactams 18. 
Dearylation and methylthiolation provided N-methylthio β-lactams 20.  
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Scheme II-4
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2.3  Biological Activity  
       Fatty ester N-methylthio β-lactams 7, 13, 15 and 20 were tested for antibacterial 
activity by the Kirby-Bauer method of disc diffusion on agar plates. Mr. Timothy Long 
and Ms. Sonja Dickey performed these assays. Table 1, 2 and 3 displays a plot of the 
microbiological data for these 20 β-lactams. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table II-1. Zones of inhibition obtained from agar well diffusion experiments using 20 µg of the test compound. The values
correspond to the diameters in mm for the zone of growth inhibition appearing around the well after 24 hours. Penicillin G (Pen G) was 
used as a reference antibiotic. Staphylococcus aureus and β-lactamase-producing strains of methicillin-resistant Staphylococcus aureus 
were obtained from a clinical testing laboratory at Lakeland Regional Medical Center, Lakeland, FL (labeled MRSA USF652-659) or 
from ATCC sources. ("nt" indicates "not tested")
 
Microorganisms                 cis-7a         cis-7b         cis-7c         cis-7d    trans-7d     cis-7e        cis-13      trans-13     Pen G
MRSA USF652                      12               17               17              11              9               0              18              18               8
MRSA USF653                      14               14               13               8               8               0              21              23              15
MRSA USF654                       8                 9                11              10              9               0              19              20              10
MRSA USF655                      14               12               13               9               9               0              20              22              14
MRSA USF656                      11               11               14              10              8               0              20              22              12                      
MRSA USF657                      12               14               14               9               9               0              19              21              12
MRSA USF658                       9                11               12               9               8               0              21              23              19
MRSA USF659                      13               13               12              10              9               0              18              19              16
S. aureus ATCC 25923          13               13               13              11             10              0              16              18              33
S. epidermidis                        12               16               12                9               8               0              nt               nt               50
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 Table II-2. Zones of inhibition obtained from agar well diffusion experiments using 20 µg of the test compound.
The values correspond to the diameters in mm for the zone of growth inhibition appearing around the well after
24 hours. Penicillin G (Pen G) was used as a reference antibiotic. Staphylococcus aureus and β-lactamase-producing 
strains of methicillin-resistant Staphylococcus aureus were obtained from a clinical testing laboratory at Lakeland 
Regional Medical Center, Lakeland, FL (labeled MRSAUSF652-659) or from ATCC sources.
 
Microorganisms               cis-15a     trans-15a    cis-15b    trans-15c  trans-15d   cis-15e   trans-15e     Pen G
MRSA USF652                      15              18              14              15              9               0              0               8
 
MRSA USF653                      12              15              12              11              8               0              0              15
MRSA USF654                      12              16              11              11              9               0              0              10
MRSA USF655                      13              16              12              13              8               0              0              14
MRSA USF656                      14              17              14              14              9               0              0              12                      
MRSA USF657                      11              15              11              12              8               0              0              12
MRSA USF658                      14              15              13              11              8               0              0              19
MRSA USF659                      13              18              13              13              9               0              0              16
S. aureus ATCC 25923          14              17              13              12              9               0              0              33
S. epidermidis                         14              15              12              11              8               0              0              50
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Table II-3  Zones of inhibition obtained from agar well diffusion experiments using 20 µg of
 the test compound. The values correspond to the diameters in mm for the zone of growth 
 inhibition appearing around the well after 24 hours. Penicillin G (Pen G) was used as a reference
 antibiotic. Staphylococcus aureus and β-lactamase-producing strains of methicillin-resistant 
 Staphylococcus aureus were obtained from a clinical testing laboratory at Lakeland Regional
 Medical Center, Lakeland, FL (labeled MRSAUSF652-659) or from ATCC sources.
 
Microorganisms                  20a            20b             20c           20d           20e       Pen G
MRSA USF652                      23              21              18              13             15               8
 
MRSA USF653                      24              20              20               9              15              15
MRSA USF654                      21              18              18               8              14              10
MRSA USF655                      23              21              19               9              16              14
MRSA USF656                      22              18              18              10             15              12                      
MRSA USF657                      20              17              15               9              14              12
MRSA USF658                      21              18              16              10             16              19
MRSA USF659                      15              17              13               8              17              16
S. aureus ATCC 25923          23              20              20               9              13              33
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2.4  Discussion 
       It is apparent that β-lactams cis-7a, cis-7b, and cis-7c are about equal in potency, 
suggesting that alkyl chain length of the benzoate ester moiety may not influence in vitro 
antimicrobial activity. However, activity drops dramatically for derivatives having seven 
carbons (cis-7d and trans-7d) or more in the ester chain, as for the inactive decyl ester 
cis-7e. Fig. 1 displays the observed structure-activity relationship for β-lactams 7. 
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Fig. 2-1 Effect of increasing R chain length on antibacterial activity 
                             against MRSA for β-lactams 5. 
 
       In addition to the fatty ester residues on the C4 aryl ring, as in the above series of 
compounds, the substitution of the C3 methoxy group for an acetoxy group also can 
provides a good opportunity to study of two series of compounds for biological activity.                        
Fig. 2 displays the structure-activity relationship for β-lactams 7 and 15. It is clear that β-
lactams 7 and 15 have about equal biological activity, suggesting that C3 methoxy and 
acetoxy moieties may exert equal influence over antimicrobial activity. However, for 
both β-lactams 7 and 15, activity drops dramatically for derivatives having seven carbons 
or more in the ester chain, as for the inactive decyl ester analogs. 
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     Fig. 2-2 Comparison of bioactivities for methoxy and acetoxy β-lactams 7 & 15. 
 
         
       It is also interesting to study side-by-side the cis and trans isomers of C3-acetoxy  
N-methylthio -lactams 15. Fig. 3 shows that there is not much difference between the 
cis and trans analogs, and once again, activity drops dramatically for derivatives having 
seven carbons or more in the ester chain. In the case of methyl ester analogs, the trans 
isomer was found to be about 10% more active than the cis analogs. 
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                  Fig. 2-3 Comparison of bioactivities for trans and cis β-lactams 15 
 
 
       Fig. 4 displays the comparison of bioactivities for ortho and para ethyl ester analogs. 
It is apparent that ortho analogs have about 40% more potent activity than that of the 
para analogs, so bioactivities depend on the position of the ester substituent on the 
phenyl ring. The reason for more potent activity of the ortho analogs is not clear yet. 
       The other hand, C3-alkyl carbonate and methyl dithiocarbonate analogs 20 are good  
candidates for examining the effect of different functionalities and chain branching on 
bioactivity at C3. Fig 5. shows the comparison of activities as increasing the bulkiness of 
the alkyl group. Upon increasing the size of alkyl group, the activity gradually drops up 
to 50% compared to the methyl and phenyl analogs. It is also apparent that the methyl 
carbonate analog has about 25% more activity than that of methyl dithiocarbonate.  
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2.5 Conclusion 
 In general, the antibacterial properties of the fatty ester N-methylthio β-lactams is 
loosely associated with lipophilicity within the C4 side chain. Activity drops off rapidly 
when more than seven carbon atoms are in the ester. However, the cis and trans 
stereochemistry and methoxy/acetoxy substitution at C3 seem to exert no significant 
effect. Ortho-substituted C4-aryl analogs have more potent activity than that of the para 
analogs.  
       Therefore, as these studies show, there is an optimal chain length for the fatty ester 
groups, with activity dropping off rapidly when more than seven carbon atoms are in the 
chain. These results gave us the idea about developing a β-lactam prodrug  system and a 
β-lactam conjugated polymer drug delivery system. The inactive form of β-lactam 
conjugated in the long cacrbon chain like the polymer can be changed to the active form 
after biological or enzymatical cleavage from polymer. In the next chaper, β-lactam 
conjugated polymeric nanoparticles are going to be described as a possible new drug 
delivery system.  
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2.6  Experimental 
       All reagents were purchased from Sigma-Aldrich Chemical Company and used 
without further purification. Solvents were obtained from Fisher Scientific Company. 
Thin layer chromatography (TLC) was carried out using EM Reagent plates with a 
fluorescence indicator (SiO2-60, F-254). Products were purified by flash chromatography 
using J.T. Baker flash chromatography silica gel (40 µm). NMR spectra were recorded in 
CDCl3 unless otherwise noted. 13C NMR spectra were proton broad-band decoupled. 
Procedure for the Synthesis of 4-(Methoxycarbonyl)benzaldehyde (3a) 
To a stirred milky solution of 4-carboxybenzaldehyde (1.00 g, 6.7 mmol) in dry methanol 
(20 ml) in an ice-water bath was added dropwise thionyl chloride (0.54 ml, 7.3 mmol). 
After 30 min, the mixture was allowed to warm to room temperature and stirred for an 
additional 8 h. The mixture was diluted with CH2Cl2 (20 ml), followed by evaporation 
under reduced pressure to 1.08 g (99%) of aldehyde 3a as an off-white solid. mp 44-45 
oC. 1H NMR (250 MHz) δ10.11 (s, 1H), 8.21 (d, J = 8.4 Hz, 2H), 7.96 (d, J = 8.4 Hz, 2H), 
3.97 (s, 3H). 13C NMR (63 MHz) δ191.6, 165.4, 139.0, 135.3, 130.0, 129.4, 61.5. 
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Procedure for the Synthesis of 4-(Alkyloxycarbonyl)benzaldehydes 3b-3e 
To a stirred milky solution of 4-carboxybenzaldehyde (1g, 6.66 mmol) and DCC (1.51g, 
7.33 mmol) in dry CH2Cl2 (20 ml) at rt was added dry ethanol (1 ml). The resultant 
mixture was refluxed for 8 h. The solvent was removed under reduced pressure to yield a 
white solid. The crude material was purified by flash column chromatography on silica 
gel (1:9 EtOAc:hexanes) to afford 0.51 g (43%) of aldehyde 3b as a colorless semi-solid. 
1H NMR (250 MHz) δ9.97 (s, 1H), 8.06 (d, J = 8.3 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H), 
4.29 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (63 MHz) δ191.6, 165.3, 
139.0, 135.2, 130.0, 129.3, 61.4, 14.1.  
4-(Pentoxycarbonyl)benzaldehyde (3c)  
Colorless semi-solid, 50%. 1H NMR (250 MHz) δ10.06 (s, 1H), 8.16 (d, J = 8.4 Hz, 2H), 
7.92 (d, J = 8.4 Hz, 2H), 4.31 (t, J = 6.7 Hz, 2H), 1.73 (m, 2H), 1.36 (m, 6H), 0.90 (m, 
3H) 13C NMR (63 MHz) δ191.6, 165.5, 139.0, 135.4, 130.1, 129.4, 65.7, 28.3, 28.1, 22.3, 
13.9.  
4-(Heptyloxycarbonyl)benzaldehyde (3d)  
Colorless semi-solid, 45%. 1H NMR (250 MHz) δ10.05 (s, 1H), 8.14 (d, J = 8.3 Hz, 2H), 
7.90 (d, J = 8.3 Hz, 2H), 4.30 (t, J = 6.7 Hz, 2H), 1.74 (m, 2H), 1.26-1.38 (m, 8H), 0.84 
(m, 3H). 13C NMR (63 MHz) δ191.6, 165.5, 139.0, 135.4, 130.0, 129.4, 65.7, 31.6, 28.9, 
28.6, 25.9, 22.5, 14.0.  
4-(Decyloxycarbonyl)benzaldehyde (3e)  
Colorless semi-solid, 36%. 1H NMR (250 MHz) δ10.08 (s, 1H), 8.17 (d, J = 8.3 Hz, 2H), 
7.93 (d, J = 8.3 Hz, 2H), 4.33 (t, J = 6.7 Hz, 2H), 1.76 (m, 2H), 1.24-1.41 (m, 14H), 0.84 
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(m, 3H). 13C NMR (63 MHz) δ191.6, 165.5, 139.0, 135.4, 130.1, 129.4, 65.7, 31.8, 29.5 
(double), 29.2 (double), 26.0, 22.6, 14.1.  
 
Procedure for the Synthesis of N-(4-Methoxyphenyl)-Substituted Imines 4. 
To a solution of p-anisidine (9.45 g, 77.0 mmol) in 50 ml of CH2Cl2 was added 
benzaldehyde (10.50 g, 64.0 mmol) and a catalytic amount of camphorsulfonic acid. The 
resultant mixture was stirred until TLC indicated the disappearance of starting materials.  
The solvent was removed under reduced pressure, and the crude material was purified by 
recrystallization from methanol to yield 17.02 g (98%) of 4a as a yellow solid. mp 157-
159 °C. 1H NMR (250 MHz) δ 8.54 (s, 1H), 8.14 (d, J = 7.9 Hz, 2H), 7.97 (d, J = 7.9 Hz, 
2H), 7.29 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 3.96 (s, 3H), 3.85 (s, 3H). 13C 
NMR (63 MHz) δ 166.3, 158.7, 156.9, 144.2, 140.2, 132.3, 129.9, 128.4, 122.4, 114.4, 
55.4, 52.3.  
An analogous procedure was used to prepare lactams 4b-e. 
4-(Ethoxycarbonyl)benzaldehyde N-(4-methoxyphenyl)imine (4b).  
Yellow solid, mp 104-107 °C, 98%. 1H NMR (250 MHz) δ 8.51 (s, 1H), 8.11 (d, J = 8.1 
Hz, 2H), 7.93 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.6 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 4.39 
(q, J = 7.1 Hz, 2H), 3.82 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (63 MHz) δ 166.2, 
158.7, 156.9, 144.2, 140.2, 132.3, 129.9, 128.3, 122.4, 114.4, 61.2, 55.5, 14.3.  
4-(Pentoxycarbonyl)benzaldehyde N-(4-methoxyphenyl)imine (4c).  
Yellow solid, mp 68-70°C, 67%. 1H NMR (250 MHz) δ 8.54 (s, 1H), 8.13 (d, J = 8.2 Hz, 
2H), 7.95 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 4.34 (t, J 
= 6.7 Hz, 2H), 3.84 (s, 3H), 1.80 (m, 2H), 1.42 (m, 4H), 0.94 (m, 3H). 13C NMR (63 
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MHz) δ 166.2, 158.7, 156.9, 144.2, 140.2, 132.3, 129.9, 128.3, 122.4, 114.4, 65.4, 55.5, 
28.4, 28.2, 22.4, 14.0.  
4-(Heptyloxycarbonyl)benzaldehyde N-(4-methoxyphenyl)imine (4d).  
Yellow solid, mp 59-60 °C, 89%. 1H NMR (250 MHz) δ 8.54 (s, 1H), 8.13 (d, J = 8.3 Hz, 
2H), 7.95 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.9 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 4.34 (t, J 
= 6.7 Hz, 2H), 3.84 (s, 3H), 1.80 (m, 2H), 1.32-1.44 (m, 8H), 0.90 (m, 3H), 13C NMR (63 
MHz) δ 166.2, 158.7, 156.8, 144.2, 140.2, 132.3, 129.9, 128.3, 122.4, 114.4, 65.4, 55.5, 
31.7, 28.9, 28.7, 26.0, 22.6, 14.1.  
4-(Decyloxycarbonyl)benzaldehyde N-(4-methoxyphenyl)imine (4e).  
Yellow solid, mp 40-41°C, 91%. 1H NMR (250 MHz) δ 8.54 (s, 1H), 8.13 (d, J = 8.2 Hz, 
2H), 7.95 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 4.34 (t, J 
= 6.7 Hz, 2H), 3.85 (s, 3H), 1.79 (m, 2H), 1.27-1.44 (m, 14H), 0.88 (m, 3H), 13C NMR 
(63 MHz) δ 166.2, 158.7, 156.9, 144.2, 140.2, 132.3, 129.9, 128.3, 122.4, 114.4, 82.6, 
65.4, 63.7, 60.8, 55.3, 52.3, 28.4, 28.1, 22.3, 20.4, 13.9. 
 
Procedure for the Formation of N-(4-Methoxyphenyl)-substituted β-Lactams 5. 
To a stirred solution of imine 4 (6.94 g, 25.8 mmol) and triethylamine (10.8 ml, 77.4 
mmol) was added dropwise over 10 minutes a solution of methoxyacetyl chloride (2.83 
ml, 37.7 mmol) in CH2Cl2. The resultant mixture was stirred at rt until TLC indicated the 
disappearance of starting material.  The solvent was removed under reduced pressure, and 
the crude material was purified by washing with ice-cold methanol to afford 6.89 g (78%) 
of lactam cis-5a as a white solid. mp 157-159 °C. 1H NMR (250 MHz) δ 8.05 (d, J = 8.1 
Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.23 (d, J = 8.9 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 5.22 
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(d, J = 4.7 Hz, 1H), 4.84 (d, J = 4.7 Hz, 1H), 3.91 (s, 3H), 3.74 (s, 3H), 3.20 (s, 3H). 13C 
NMR (63 MHz) δ 166.7, 163.4, 156.5, 138.7, 130.4, 130.3, 129.8, 128.0, 118.7, 114.4, 
84.9, 61.4, 58.5, 55.4, 52.2.  
An analogous procedure was used to prepare lactams 5b-e. 
  
cis-4-(4-Ethoxycarbonylphenyl)-3-methoxy-N-(4-methoxyphenyl)-2-azetidinone (cis-
5b).  
White solid, mp 104-107 °C, 18%. 1H NMR (250 MHz) δ 8.05 (d, J = 8.2 Hz, 2H). 7.46 
(d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.9 Hz, 2H), 6.77 (d, J = 8.9 Hz, 2H), 5.22 (d, J = 4.8 Hz, 
1H), 4.85 (d, J = 4.8 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.73 (s, 3H), 3.19 (s, 3H), 1.38 (t, 
J = 7.1 Hz, 3H), 13C NMR (63 MHz) δ 166.1, 163.4, 156.4, 138.6, 130.8, 130.3, 129.7, 
127.9, 118.6, 114.3, 84.9, 61.4, 61.1, 58.5, 55.4, 14.3.  
cis-3-Methoxy-N-(4-methoxyphenyl)-4-(4-pentoxycarbonylphenyl)-2-azetidinone 
(cis-5c).  
White solid, mp 68-70 °C, 17%. 1H NMR (250 MHz) δ 8.08 (d, J = 8.3 Hz, 2H). 7.49 (d, 
J = 8.3 Hz, 2H), 7.26 (d, J = 9.0 Hz, 2H), 6.81 (d, J = 9.0 Hz, 2H), 5.22 (d, J = 4.7 Hz, 
1H), 4.88 (d, J = 4.7 Hz, 1H), 4.34 (t, J = 6.4 Hz, 2H), 3.78 (s, 3H), 3.52 (s, 3H), 1.79 
(quintet, J = 6.9 Hz, 2H), 1.43 (m, 4H), 0.94 (t, J = 6.9 Hz, 3H), 13C NMR (63 MHz) δ 
166.2, 163.4, 156.4, 138.6, 130.8, 130.3, 129.8, 127.9, 118.7, 114.4, 85.0, 65.2, 61.4, 58.6, 
55.4, 28.4, 28.2, 22.3, 14.0.  
cis-4-(4-Heptyloxycarbonylphenyl)-3-methoxy-N-(4-methoxyphenyl)-2-azetidinone 
(cis-5d).  
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White solid, mp 51-53°C, 19%. 1H NMR (250 MHz) δ 8.06 (d, J = 8.1 Hz, 2H), 7.47 (d, 
J = 8.1 Hz, 2H), 7.24 (d, J = 8.9 Hz, 2H), 6.79 (d, J = 8.9 Hz, 2H), 5.23 (d, J = 4.7 Hz, 
1H), 4.85 (d, J = 4.7 Hz, 1H), 4.31 (t, J = 6.5 Hz, 2H), 3.74 (s, 3H), 3.21 (s, 3H), 1.75 
(m, 2H), 1.30-1.38 (m, 8H), 0.89 (m, 3H). 13C NMR (63 MHz) δ 166.2, 163.4, 156.4, 
138.6, 130.8, 130.3, 129.8, 127.9, 118.7, 114.4, 85.0, 65.2, 61.4, 58.5, 55.4, 31.7, 28.9, 
28.7, 26.0, 22.6, 14.0.  
trans-4-(4-Heptyloxycarbonylphenyl)-3-methoxy-N-(4-methoxyphenyl)-2-
azetidinone (trans-5d).  
White solid, mp 55-57°C, 18%. 1H NMR (250 MHz) δ 8.09 (d, J = 8.1 Hz, 2H), 7.42 (d, 
J = 8.1 Hz, 2H), 7.23 (d, J = 8.9 Hz, 2H), 6.80 (d, J = 8.9 Hz, 2H), 4.97 (app s, 1H), 
4.43 (app s, 1H), 4.34 (t, J = 6.4 Hz, 2H), 3.75 (s, 3H), 3.60 (s, 3H), 1.78 (quintet, J = 
6.5 Hz, 2H), 1.22-1.38 (m, 8H), 0.90 (m, 3H). 13C NMR (63 MHz) δ 166.0, 163.1, 156.5, 
141.3, 131.0, 130.5, 130.2, 126.0, 118.8, 114.4, 91.2, 65.3, 62.8, 58.2, 55.4, 31.7, 29.0, 
28.7, 26.0, 22.6, 14.1.  
cis-4-(4-Decyloxycarbonylphenyl)-3-methoxy-N-(4-methoxyphenyl)-2-azetidinone 
(cis-5e).  
White solid, mp 95-96°C, 63%. 1H NMR (250 MHz) δ 8.05 (d, J = 8.2 Hz, 2H), 7.46 (d, 
J = 8.2 Hz, 2H), 7.23 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.0 Hz, 2H), 5.22 (d, J = 4.7 Hz, 
1H), 4.85 (d, J = 4.7 Hz, 1H), 4.30 (t, J = 6.4 Hz, 2H), 3.74 (s, 3H), 3.21 (s, 3H), 1.75 
(m, 2H), 1.26-1.42 (m, 14H), 0.89 (m, 3H). 13C NMR (63 MHz) δ 166.2, 163.4, 156.5, 
138.6, 130.9, 130.3, 129.8, 127.9, 118.7, 114.4, 85.0, 65.3, 61.4, 58.6, 55.4, 31.8, 29.5 
(double), 29.3 (double), 28.7, 26.0, 22.6, 14.1.  
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Procedure for the N-Dearylation of N-(4-Methoxylphenyl)-substituted β-Lactams 6. 
To a solution of cis-5a (1.00 g, 2.93 mmol) in 15 ml of acetonitrile in ice-water bath, 
was added ceric ammonium nitrate (4.82 g, 8.79 mmol) in 15 ml of water. The resultant 
mixture was stirred for 5 minutes, and 20 ml of water was added.  The solution was 
extracted (3 x 25 ml) with EtOAc.  The combined organic layers were washed with 75 
ml of 5% NaHSO3, 5% NaCO3, and dried over anhydrous MgSO4. The solvent was 
removed under reduced pressure to yield a brown oil, which after purification by flash 
column chromatography on silica gel (1:2 EtOAc:hexanes) afforded 0.45 g (65% yield) 
of lactam cis-6a as a brown oil. 1H NMR (250 MHz) δ 8.03 (d, J = 8.3 Hz, 2H), 7.43 (d, 
J = 8.3 Hz, 2H), 6.40 (bs, 1H), 4.89 (d, J = 4.5 Hz, 1H), 4.77 (dd, J = 4.5, 2.7 Hz, 1H), 
3.90 (s, 3H), 3.15 (s, 3H).  
An analogous procedure was used to prepare lactams 6b-e. 
cis-4-(4-Ethoxycarbonylphenyl)-3-methoxy-2-azetidinone (cis-6b).  
Brown oil, 72%. 1H NMR (250 MHz) δ 8.08 (d, J = 8.2 Hz, 2H). 7.47 (d, J = 8.2 Hz, 
2H), 6.70 (bs, 1H), 4.93 (d, J = 4.5 Hz, 1H), 4.81 (dd, J = 4.5, 2.9 Hz, 1H), 4.40 (q, J = 
7.1 Hz, 2H), 3.19 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H).  
cis-3-Methoxy-4-(4-pentoxycarbonylphenyl)-2-azetidinone (cis-6c).  
Brown oil, 19%. 1H NMR (250 MHz) δ 8.09 (d, J = 8.2 Hz, 2H). 7.48 (d, J = 8.2 Hz, 
2H), 6.36 (bs, 1H), 4.95 (d, J = 4.7 Hz, 1H), 4.83 (dd, J = 4.7, 2.8 Hz, 1H), 4.35 (t, J = 
6.7 Hz, 2H), 3.22 (s, 3H), 1.79 (quintet, J = 6.7 Hz, 2H), 1.43 (m, 4H), 0.94 (t, J = 6.9 
Hz, 3H).  
cis-4-(4-Heptyloxycarbonylphenyl)-3-methoxy-2-azetidinone (cis-6d)  
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Brown oil, 89%. 1H NMR (250 MHz) δ 8.06 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.3 Hz, 
2H), 6.38 (bs, 1H), 4.92 (d, J = 4.5 Hz, 1H), 4.80 (dd, J = 4.5, 2.8 Hz, 1H), 4.31 (t, J = 
6.7 Hz, 2H), 3.18 (s, 3H), 1.78 (quintet, J = 6.5 Hz, 2H), 1.22-1.38 (m, 8H), 0.89 (m, 
3H).  
trans-4-(4-Heptyloxycarbonylphenyl)-3-methoxy-2-azetidinone (trans-6d).  
Brown oil, 88%. 1H NMR (250 MHz) δ 8.11 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 
2H), 6.35 (bs, 1H), 4.64 (app s, 1H), 4.43 (app s, 1H), 4.34 (t, J = 6.4 Hz, 2H), 3.60 (s, 
3H), 1.78 (quintet, J = 6.5 Hz, 2H), 1.22-1.38 (m, 8H), 0.90 (m, 3H).  
cis-4-(4-Decyloxycarbonylphenyl)-3-methoxy-2-azetidinone (cis-6e).  
Brown oil, 91%. 1H NMR (250 MHz) δ 8.02 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 
2H), 6.89 (bs, 1H), 4.89 (d, J = 4.5 Hz, 1H), 4.77 (dd, J = 4.5, 2.5 Hz, 1H), 4.28 (t, J = 
6.6 Hz, 2H), 3.13 (s, 3H), 1.75 (quintet, J = 7.1 Hz, 2H), 1.26-1.42 (m, 14H), 0.89 (t, J = 
6.7 Hz, 3H).  
 
Procedure for the N-Methylthiolation of Lactams 7. 
To a solution of cis-6a (455 mg, 1.91 mmol) in 10 ml of dry CH2Cl2 was added N-
(methylthio)phthalimide (410 mg, 2.10 mmol) and 0.25 ml of triethylamine. The 
resultant mixture was refluxed overnight.  The solvent was removed under reduced 
pressure to yield a brown solid.  The brown solid was redissolved in CH2Cl2 and washed 
with 1% aqueous NaOH.  The organic layer was dried over anhydrous MgSO4.  The 
solvent was removed under reduced pressure to yield a brown oil, which after 
purification by column chromatography on silica gel (1:4 EtOAc:hexanes) yielded 0.356 
g (66%) of cis-7a as a white solid. mp 118-120 °C. 1H NMR (250 MHz) δ 8.03 (d, J = 
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8.1 Hz, 2H). 7.45 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 8.9 Hz, 2H), 6.77 (d, J = 8.9 Hz 2H), 
3.18 (s, 3H), 5.22 (d, J = 4.7 Hz, 1H), 4.84 (d, J = 4.7 Hz, 1H), 3.90 (s, 3H), 3.72 (s, 3H). 
13C NMR (63 MHz) δ 170.2, 167.0, 138.7, 130.7, 129.6, 128.8, 86.7, 65.8, 58.5, 52.2, 
22.1.  
An analogous procedure was used to prepare lactams 7b-e. 
cis-4-(4-Ethoxycarbonylphenyl)-3-methoxy-N-methylthio-2-azetidinone (cis-7b). 
White solid, mp 113-114 °C, 70%. 1H NMR (250 MHz)  δ 8.03 (d, J = 8.1 Hz, 2H), 7.45 
(d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.9 Hz, 2H), 6.77 (d, J = 8.9 Hz, 2H), 5.22 (d, J = 4.8 
Hz, 1H), 4.84 (d, J = 4.8 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.73 (s, 3H), 3.19 (s, 3H), 
1.38 (t, J = 7.1 Hz, 3H). 13C NMR (63 MHz) δ 170.1, 166.2, 138.6, 131.0, 129.5, 128.8, 
86.7, 65.8, 61.1, 58.4, 22.1, 14.3.  
cis-3-Methoxy-N-methylthio-4-(4-pentoxycarbonylphenyl)-2-azetidinone (cis-7c). 
White solid, mp 84-85 °C, 79%. 1H NMR (250 MHz) δ 8.07 (d, J = 8.0 Hz, 2H), 7.44 (d, 
J = 8.0 Hz, 2H), 4.88 (d, J = 4.8 Hz, 1H), 4.82 (d, J = 4.8 Hz, 1H), 4.32 (t, J = 6.5 Hz, 
2H), 3.17 (s, 3H), 2.39 (s, 3H), 1.77 (m, 2H), 1.41 (m, 4H), 0.93 (t, J = 6.5 Hz, 3H). 13C 
NMR (63 MHz) δ 170.2, 166.3, 138.6, 131.1, 129.5, 128.8, 86.8, 66.0, 65.4, 58.4, 28.3, 
28.2, 22.1, 22.0, 13.9.  
cis-4-(4-Heptyloxycarbonylphenyl)-3-methoxy-N-methylthio-2-azetidinone (cis-7d). 
White solid, mp 51-52 °C, 70%. 1H NMR (250 MHz)  δ 8.08 (d, J = 8.3 Hz, 2H), 7.45 
(d, J = 8.3 Hz, 2H), 4.88 (d, J = 4.9 Hz, 1H), 4.82 (d, J = 4.9 Hz, 1H), 4.33 (t, J = 6.6 Hz, 
2H), 3.18 (s, 3H), 2.39 (s, 3H), 1.75 (m, 2H), 1.25-1.42 (m, 8H), 0.90 (m, 3H). 13C 
NMR (63 MHz) δ 170.1, 166.1, 138.5, 131.3, 129.5, 128.8, 87.0, 65.4, 65.0, 58.4, 31.7, 
29.1, 28.9, 26.0, 23.0, 22.6, 14.1.  
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trans-4-(4-Heptyloxycarbonylphenyl)-3-methoxy-N-methylthio-2-azetidinone 
(trans-7d).  
White solid, 53-55 °C, 68%. 1H NMR (250 MHz) δ 8.09 (d, J = 7.9 Hz, 2H). 7.38 (d, J 
= 7.9 Hz, 2H), 4.67 (app s, 1H), 4.44 (app s, 1H), 4.33 (t, J = 6.5 Hz, 2H), 3.53 (s, 3H), 
2.43 (s, 3H), 1.77 (m, 2H), 1.25-1.41 (m, 8H), 0.89 (m, 3H). 13C NMR (63 MHz) δ 
170.1, 166.0, 140.9, 131.2, 130.3, 126.8, 91.7, 66.2, 65.4, 58.4, 31.7, 29.7, 28.9, 26.0, 
22.6, 21.8, 14.0.  
cis-4-(4-Decyloxycarbonylphenyl)-3-methoxy-N-methylthio-2-azetidinone (cis-7e). 
White solid, 45-46 °C, 81%. 1H NMR (250 MHz)  δ 8.06 (d, J = 8.0 Hz, 2H), 7.43 (d, J 
= 8.0 Hz, 2H), 4.88 (d, J = 5.0 Hz, 1H), 4.82 (d, J = 5.0 Hz, 1H), 4.31 (t, J = 6.7 Hz, 
2H), 3.15 (s, 3H), 2.38 (s, 3H), 1.76 (m, 2H), 1.26-1.42 (m, 14H), 0.87 (m, 3H), 13C 
NMR (63 MHz) δ 170.1, 166.2, 138.6, 131.0, 129.5, 128.8, 86.7, 65.8, 65.3, 58.5, 31.8, 
29.5, 29.3, 28.7, 26.0, 22.7, 22.1, 14.0.  
 
Procedure for the Synthesis of 2-Ethoxycarbonylbenzaldehyde (9)  
To a stirred solution of 2-carboxybenzaldehyde 8 (5.00 g, 33.3 mmol) in dry acetone (20 
ml) was added K2CO3 (4.60g, 40.0 mmol) and the solution was stirred for 1h. To this 
was added dropwise a solution of ethyl iodide (3.2 ml, 40 mmol) in dry acetone (1 ml), 
and the mixture was refluxed for overnight. The solvent was removed under reduced 
pressure to yield a brown semi-solid. The brown solid was redissolved in EtOAc, and 
washed with water. The organic layer was dried over anhydrous MgSO4. The crude 
material was purified by column chromatography on silica gel (1:9 EtOAc:hexanes) to 
yield 1.07 g (18%) of aldehyde 9 as a colorless semi-solid. 1H NMR (250 MHz) δ 10.58 
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(s, 1H), 7.88-7.96 (m, 2H), 7.53-7.63 (m, 2H), 4.41 (q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 
Hz, 3H). 13C NMR (63 MHz) δ 192.2, 136.9, 132.9, 132.4, 132.2, 130.7, 130.3, 128.3, 
62.0, 14.2. 
 
Procedure for the Synthesis of N-(4-Methoxyphenyl)-4-ethoxycarbonyl 
phenylimine (10).  
To a solution of p-anisidine (0.55 g, 4.5 mmol) in 10 ml of CH2Cl2 was added aldehyde 
9 (0.80 g, 4.5 mmol) and a catalytic amount of camphorsulfonic acid. The resultant 
mixture was stirred at rt until TLC indicated the disappearance of both starting materials.  
The solvent was removed under reduced pressure, and the crude material was purified 
by recrystallization from methanol to yield 0.76 g (60%) of imine 9 as a yellow solid. 
mp 52-53 °C. 1H NMR (250 MHz) δ 9.23 (s, 1H), 8.22 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 
7.5 Hz, 1H), 7.58 (t, J = 7.1 Hz, 1H), 7.46 (t, J = 7.4 Hz, 1H), 7.28 (d, J = 8.6 Hz, 2H), 
6.91 (d, J = 8.6 Hz, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H),1.38 (t, J = 7.1 Hz, 3H). 
13C NMR (63 MHz) δ 166.9, 158.3, 157.6, 144.8, 137.3, 132.1, 130.7, 130.3, 129.9, 
128.1, 122.5, 114.2, 61.3, 55.4, 14.2.  
 
Synthesis of 4-(2-Ethoxycarbonylphenyl)-3-methoxy-N-(4-methoxyphenyl)-2-
azetidinone (cis and trans adduct).  
To a stirred solution of imine 4 (0.34 g, 1.21 mmol) and triethylamine (0.51 ml, 3.63 
mmol) was added dropwise over 10 minutes a solution of methoxyacetyl chloride (0.22 
ml, 2.42 mmol) in CH2Cl2. The resultant mixture was refluxed for overnight. The solvent 
was removed under reduced pressure to yield a brown oil. The crude material was 
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purified by flash column chromatography on silica gel (1:4 EtOAc:hexanes) to afford 
0.18 g (36%) of lactam 11, Brown semisolid (cis:trans = 1:1 mixture), 1H NMR (250 
MHz)  δ 1.40 (t, J=7.1 Hz, 3H), 3.19 (s, 3H), 3.73 (s, 3H), 4.37 (q, J=7.1 Hz, 2H), 4.84 (d, 
J=4.8 Hz, 1H,), 5.22 (d, J=4.8 Hz, 1H,), 6.77 (d, J=8.9 Hz 2H), 7.22 (d, J=8.9 Hz, 2H), 
7.45 (d, J=8.1 Hz, 2H), 8.03 (d, J=8.1 Hz, 2H). 13C NMR (63 MHz) δ 14.3, 22.1, 58.4, 
61.1, 65.8, 86.7, 128.8, 129.5, 131.0, 138.6, 166.2, 170.1. 
Procedure for synthesis of 3-Methoxy-4-(2-ethyloxycarbonyl)phenyl-2-azetidinone 
(12) 
To a solution of 10 (0.18 g, 0.52 mmol) in 1 ml of CH3CN in an ice-water bath was added 
a solution of ceric ammonium nitrate (0.86 g, 1.57 mmol) in 1 ml of water. The resultant 
mixture was stirred for 5 min, and 2 mL of water was added.  The solution was extracted 
(3 x 5 ml) with EtOAc.  The combined organic layers were washed with 5% NaHSO3, 
5% NaHCO3, and dried over anhydrous MgSO4. The solvent was removed under reduced 
pressure to yield a brown oil, which was purified by flash column chromatography on 
silica gel (1:2 EtOAc:hexanes) to afford 47 mg (36%) of lactam 11 as a brown semi-solid 
(1:1 cis:trans mixture). 1H NMR (250 MHz) δ 8.08 (d, J = 7.5 Hz, 1H). 8.02 (dd, J = 7.5, 
1.5 Hz, 2H), 7.41 (m, 8H), 7.28 (m, 8H), 6.78 (two d, J = 9.0 Hz, 6H), 6.01 (d, J = 5.1 Hz, 
1H), 5.98 (s, 2H), 4.95 (d, J = 5.1 Hz, 1H), 4.43 (q, J = 7.1 Hz, 4H), 3.71 (s, 6H), 3.59 (s, 
6H), 1.42 (two t, J = 7.1 Hz, 6H), 13C NMR (63 MHz) δ 166.9, 166.6, 164.6, 163.9, 156.3, 
137.8, 136.0, 132.8, 132.4, 131.2, 131.0, 130.7, 130.3, 129.4, 129.2, 128.1, 127.8, 126.1, 
118.9, 118.6, 114.3, 91.5, 85.6, 61.5, 61.2, 60.3, 59.1, 58.9, 57.9, 55.3, 30.9, 14.3.  
 
Procedure for the Synthesis of N-Methylthiolation of β-Lactams 13. 
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To a solution of 12 (47 mg, 0.19 mmol) in 2 ml of dry CH2Cl2 was added N-
(methylthio)phthalimide (55 mg, 0.28 mmol) and 3-5 drops of triethylamine. The 
resultant mixture was refluxed overnight.  The solvent was removed under reduced 
pressure to yield a brown solid.  The brown solid was redissolved in methylene chloride, 
and washed with 1% sodium hydroxide.  The organic layer was dried over magnesium 
sulphate.  The solvent was removed under reduced pressure to yield a brown semi-solid. 
The crude material was purified by column chromatography on silica gel using a gradient 
elution (1:19, 1:9 and 1:4 EtOAc:hexanes) to yield 23 mg (35%) of cis-lactam 13a and 24 
mg (37%) of trans-lactam 13b as white solids (total 72% yield).  
cis-4-(2-Ethoxycarbonylphenyl)-3-methoxy-N-methylthio-2-azetidinone (13a).  
White solid, mp 95-97 °C, 35%. 1H NMR (250 MHz) δ 8.06(m, 1H). 7.61(m, 1H), 7.43 
(m, 2H), 5.72 (d, J = 5.1 Hz, 1H), 4.95 (d, J = 5.1 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 3.23 
(s, 3H), 2.48 (s, 3H), 1.43 (t, J = 7.1 Hz 3H). 13C NMR (63 MHz) δ 171.3, 166.7, 136.1, 
132.4, 130.9, 129.8, 127.9, 87.6, 63.8, 61.2, 58.9, 29.7, 21.5, 14.3.  
trans-4-(2-Ethoxycarbonylphenyl)-3-methoxy-N-methylthio-2-azetidinone (13b). 
White solid, mp 75-76 °C, 37%. 1H NMR (250 MHz) δ 8.01 (m, 1H), 7.58 (m, 1H), 
7.43(m, 1H), 7.29 (m, 1H), 5.71 (d, J = 1.9 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 4.40 (d, J = 
1.9 Hz, 1H), 3.56 (s, 3H), 2.46 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). 13C NMR (63 MHz) 
δ 171.1, 166.8, 137.6, 132.6, 131.1, 130.3, 128.2, 126.3, 92.3, 62.0, 61.5, 58.2, 21.6, 14.2. 
  
Procedure for the Synthesis of 3-Acetoxy-N-(4-Methoxyphenyl)-substituted β–
Lactams 14.  
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To a stirred solution of imine 4a (0.50 g, 1.9 mmol) and triethylamine (0.56 g, 5.6 mmol) 
was added dropwise over 10 min a solution of acetoxyacetyl chloride (0.24 ml, 2.2 mmol ) 
in dry CH2Cl2 (10 ml). The resultant mixture was stirred at rt for overnight.  The solvent 
was removed under reduced pressure, and the crude material was purified by column 
chromatography on silica gel by gradient elution (1:9 then 1:4 EtOAc: hexanes) to yield 
175 mg (25%) of lactam 14a (1:1 cis:trans mixture) as a brown semi-solid. 1H NMR (250 
MHz) δ 8.00 (two d, J = 8.9 Hz, 4H), 7.38 (two d, J = 8.9 Hz, 4H), 7.20 (two d, J = 8.9 
Hz, 4H), 6.77 (two d, J = 8.9 Hz, 4H), 5.94 (d, J = 4.8 Hz, 1H), 5.37 (d, J = 4.8 Hz, 1H), 
5.32 (s, 1H, trans isomer), 4.94 (s, 1H, trans isomer), 3.89 (s, 6H), 3.72 (s, 3H), 3.71 (s, 
3H), 2.17(s, 3H), 1.67 (s, 3H).  
An analogous procedure was used to prepare β-lactams 14b-e. 
3-Acetoxy-4-(4-ethoxycarbonylphenyl)-N-(4-methoxyphenyl)-2-azetidinone (14b). 
Brown semi-solid, 20:1 cis:trans mixture, 43%. Data for cis isomer:1H NMR (250 MHz) 
δ 8.02 (d, J = 7.9 Hz, 2H). 7.37 (d, J = 7.9 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 6.79 (d, J = 
8.5 Hz, 2H), 5.96 (d, J = 4.5 Hz, 1H), 5.38 (d, J = 4.5 Hz, 1H), 4.36 (q, J = 7.0 Hz, 2H), 
3.73 (s, 3H), 1.69 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). 13C NMR (63 MHz) δ 169.1, 166.0, 
161.0, 156.7, 137.4, 130.9, 130.0, 129.7, 127.9, 118.7, 114.4, 76.3, 61.2, 61.1, 55.4, 19.9, 
14.3.  
3-Acetoxy-N-(4-methoxyphenyl)-4-(4-pentoxycarbonylphenyl)-2-azetidinone (14c). 
Brown semi-solid, 1:5 cis:trans mixture, 12%. Data for the trans isomer: 1H NMR (250 
MHz) δ 8.03 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H), 7.18 (d, J = 8.9 Hz, 2H), 6.76 
(d, J = 8.9 Hz, 2H), 5.31 (s, 1H), 4.95 (s, 1H), 4.27 (t, J = 6.5 Hz, 2H), 3.70 (s, 3H), 2.17 
(s, 3H), 1.72 (m, 2H), 1.37 (m, 4H), 0.89 (m, 3H). 13C NMR (63 MHz) δ 169.7, 165.9, 
 44
160.7, 156.6, 140.0, 131.1, 130.3, 129.9, 126.4, 118.8, 114.4, 82.3, 65.2, 63.3, 55.3, 28.3, 
28.1, 20.4, 13.9.  
3-Acetoxy-N-(4-methoxyphenyl)-4-(4-heptyloxycarbonylphenyl)-2-azetidinone (14d). 
Brown semi-solid, 1:2 cis:trans mixture, 40%. 1H NMR (250 MHz) δ 8.04 (two d, J = 8.6 
Hz, 3H), 7.42 (two d, J = 8.6 Hz, 3H), 7.20 (two d, J = 8.7 Hz, 3H), 6.79 (two d, J = 8.7 
Hz, 3H), 5.97 (d, J = 4.6 Hz, 0.5H, cis isomer), 5.39 (d, J = 4.6 Hz, 0.5H, cis isomer), 
5.33 (s, 1H, trans isomer), 4.95 (s, 1H, trans isomer), 4.30 (t, J = 6.5 Hz, 3H), 3.73 (s, 
4.5H), 2.19 (s, 3H), 1.74 (m, 3H), 1.69 (s, 1.5 H), 1.25-1.37 (m, 12H), 0.88 (m, 4.5H).  
3-Acetoxy-4-(4-decyloxycarbonylphenyl)-N-(4-methoxyphenyl)-2-azetidinone (14e). 
Brown semi-solid, 1:1 cis:trans mixture, 57%. 1H NMR (250 MHz) δ 8.04 (two d, J = 8.5 
Hz, 4H). 7.40 (two d, J = 8.5 Hz, 4H), 7.22 (two d, J = 8.9 Hz, 4H), 6.79 (two d, J = 8.9 
Hz, 4H), 5.96 (d, J = 4.8 Hz, 1H, cis isomer), 5.39 (d, J = 4.8 Hz, 1H, cis isomer), 5.33 (s, 
1H, trans isomer), 4.96 (s, 1H, trans isomer), 4.38 (m, 4H), 3.74 (s, 3H), 3.73 (s, 3H), 
2.19 (s, 6H), 1.73 (m, 4H), 1.69 (s, 6 H), 1.26-1.69 (m, 28H), 0.87 (m, 6H). 
 
Procedure for the Synthesis of N-Methylthio-substituted β–Lactams 15. 
To a solution of 14a (100 mg, 0.27 mmol) in 2.5 ml of CH3CN in an ice-water bath was 
added ceric ammonium nitrate (0.450 g, 0.81 mmol) in 2.5 ml of water. The resultant 
mixture was stirred for 5 min, and 5 ml of water was added.  The solution was extracted 
(3x5 ml) with EtOAc.  The combined organic layers were washed with 5% NaHSO3, 5% 
NaHCO3, and dried over anhydrous MgSO4. The solvent was removed under reduced 
pressure to yield a crude brown oil, which was dissolved in 10 ml of dry CH2Cl2 and N-
(methylthio)phthalimide (52 mg, 0.268 mmol) and 3-5 drops of triethylamine were added. 
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The resultant mixture was refluxed for overnight. The solvent was removed under 
reduced pressure to yield a brown solid.  The brown solid was redissolved in CH2Cl2, and 
washed with 1% NaOH. The organic layer was dried over anhydrous MgSO4. The 
solvent was removed under reduced pressure to yield a brown semi-solid, which was 
purified by column chromatography on silica gel with gradient elution (1:9 then 1:4 
EtOAc:hexanes) to yield 23.6 mg (18%) of a brown semi-solid containing lactams as a 
mixture of cis:trans isomers. The cis and trans isomers were separated by 
recrystallization in methanol to give cis-15a (8 mg) and trans-15a (11 mg) in combined 
18% yield. 
cis-3-Acetoxy-4-(4-methoxycarbonylphenyl)-N-methylthio-2-azetidinone (cis-15a). 
White solid, mp 81-83 °C, 8%. 1H NMR (250 MHz) δ 8.05 (d, J = 8.2 Hz, 2H), 7.35 (d, J 
= 8.2 Hz, 2H), 5.92 (d, J = 5.0 Hz, 1H), 5.08 (d, J = 5.0 Hz, 1H), 3.93 (s, 3H), 2.45 (s, 
3H), 1.69 (s, 3H). 13C NMR (63 MHz) δ 168.7, 168.1, 166.5, 137.6, 130.8, 129.5, 128.6, 
78.1, 65.4, 52.2, 22.1, 19.8.  
trans-3-Acetoxy-4-(4-methoxycarbonylphenyl)-N-methylthio-2-azetidinone (trans-
15a).  
White solid, mp 66-68 °C, 10%. 1H NMR (250 MHz) δ 8.09(d, J = 8.2 Hz, 2H), 7.40 (d, J 
= 8.2 Hz, 2H), 5.38 (d, J = 1.5 Hz, 1H), 4.72 (d, J = 1.5 Hz, 1H), 3.92 (s, 3H), 2.43 (s, 
3H), 2.16 (s, 3H). 13C NMR (63 MHz) δ 169.4, 168.0, 166.4, 140.0, 131.0, 130.2, 127.1, 
82.7, 66.0, 52.3, 21.8, 20.4.  
An analogous procedure was used to prepare lactams 15b-e. 
cis-3-Acetoxy-4-(4-ethoxycarbonylphenyl)-N-methylthio-2-azetidinone (cis-15b). 
White solid, mp 95-97 °C, 12%. 1H NMR (250 MHz) δ 8.06 (d, J = 8.3 Hz, 2H), 7.35 (d, 
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J = 8.3 Hz, 2H), 5.93 (d, J = 5.0 Hz, 1H), 5.07 (d, J = 5.0 Hz, 1H), 4.39 (q, J = 7.1 Hz, 
2H), 2.45 (s, 3H), 1.71 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). 13C NMR (63 MHz) δ 14.3, 20.0, 
22.1, 61.2, 65.4, 78.1, 128.6, 129.5, 131.1, 138.0, 166.9, 168.6, 169.2. 
3-Acetoxy-N-methylthio-4-(4-pentyloxycarbonylphenyl)-2-azetidinone (trans-15c). 
Brown oil, 1:7 cis:trans mixture, 5%. Data for trans isomer: 1H NMR (250 MHz) δ 
8.11(d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 5.39 (d, J = 1.9 Hz, 1H), 4.72 (d, J = 
1.9 Hz, 1H), 4.33 (t, J = 6.6 Hz, 2H), 2.45 (s, 3H), 2.18 (s, 3H), 1.78 (m, 2H), 1.42 (m, 
4H), 0.91 (m, 3H). 13C NMR (63 MHz) δ 7.8, 20.6, 23.7, 24.3, 28.1, 28.4, 65.4, 66.1, 
82.7, 127.1, 130.2, 131.2, 139.9, 166.4, 167.9, 169.3. 
trans-3-Acetoxy-4-(4-heptyloxycarbonylphenyl)-N-methylthio-2-azetidinone (trans-
15d). 
 Brown oil, 2%. 1H NMR (250 MHz) δ 8.05 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 
5.35 (app s, 1H), 4.70 (app s, 1H), 4.28 (t, J = 6.6 Hz, 2H), 2.40 (s, 3H), 2.12 (s, 3H), 
1.72 (m, 2H), 1.21-1.36 (m, 8H), 0.84 (m, 3H). 13C NMR (63 MHz) δ 169.4, 168.0, 165.9, 
139.8, 131.3, 130.1, 127.1, 82.7, 65.9, 65.3, 31.6, 28.9, 28.6, 25.9, 22.1, 21.7, 20.3, 14.0.  
cis-3-Acetoxy-4-(4-decyloxycarbonylphenyl)-N-methylthio-2-azetidinone (cis-15e). 
Brown oil, 9%. 1H NMR (250 MHz) δ 8.06 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 
5.93 (d, J = 5.0 Hz, 1H), 5.08 (d, J = 5.0 Hz 1H), 4.33 (t, J = 6.7 Hz, 2H), 2.46 (s, 3H), 
1.77 (m, 2H), 1.71 (s, 3H), 1.28-1.43 (m, 14H), 0.88 (t, J = 6.2 Hz, 3H). 13C NMR (63 
MHz) δ 168.9, 168.3, 166.6, 137.7, 131.1, 129.5, 128.6, 78.1, 65.4, 31.9, 29.5, 29.3, 28.6, 
26.0, 22.1, 19.9, 14.1.  
trans-3-Acetoxy-4-(4-decyloxycarbonylphenyl)-N-methylthio-2-azetidinone (trans-
15e).  
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Brown oil, 12%. 1H NMR (250 MHz) δ 8.07 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3 Hz, 2H), 
5.37 (d, J = 2.0 Hz, 1H), 4.71 (d, J = 2.0 Hz, 1H), 4.30 (t, J = 6.6 Hz, 2H), 2.42 (s, 3H), 
2.14 (s, 3H), 1.74 (m, 2H), 1.24-1.40 (m, 14H), 0.85 (m, 3H). 13C NMR (63 MHz) δ 
169.4, 168.0, 165.9, 139.8, 131.3, 130.2, 127.1, 82.7, 66.0, 65.3, 31.8, 29.5, 29.2, 28.6, 
26.0, 22.6, 21.8, 20.3, 14.1.  
Procedure for the Synthesis of 3-Acetoxy-N-(4-methoxyphenyl)-4-phenyl-2-
azetidinone (16).  
To a stirred solution of N-(4-methoxyphenyl)imine (5.31 g, 25.2 mmol) and triethylamine 
(7.64 g, 75.5 mmol) was added a solution of acetoxyacetyl chloride (5.15 g, 37.7 mmol) 
in methylene chloride dropwise over 10 minutes. The resultant mixture was stirred at rt 
until TLC indicated the disappearance of starting material.  The solvent was removed 
under reduced pressure, and the crude material was purified by washing with ice-cold 
methanol to give 6.89 g (89%) of 16 as white solid, mp 153-155 oC. 1H NMR (250 MHz) 
δ 7.34-7.30 (t, 5H), 7.28 (d, J = 8.9 Hz, 2H) 6.79 (d, J = 8.9 Hz, 2H), 5.92 (d, J = 4.8 Hz, 
1H), 5.33 (d, J = 4.8 Hz, 1H), 3.74 (s, 3H), 1.66 (s, 3H). 13C NMR (63 MHz) δ 169.1, 
161.2, 156.5, 132.2, 130.2, 128.7, 128.4, 127.8, 118.7, 61.3, 55.3, 19.7. 
 
Procedure for the Synthesis of 3-Hydroxy-N-(4-methoxyphenyl)-4-phenyl-2-
azetidinone (17).  
To a solution of β-lactam 15 (21.2 g, 68.3 mmol) in 500 ml of acetone was added KOH 
(3.83 g, 68.3 mmol) in 50 ml of methanol.  The resultant mixture was stirred for 5 
minutes, and 300 ml of water was added.  The product was precipitated and isolated by 
filtration to yield 18.0 g (98%) of 17 as a white solid, mp 199-202 oC. 1H NMR (250 
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MHz) δ 7.44-7.28 (m, 7H), 6.83-6.79 (q, 2H), 5.29 (d, J = 5.2 Hz, 1H), 5.90 (d, J = 5.2 
Hz, 1H), 3.76 (s, 3H), 2.10 (bs, 1H). 13C NMR (63 MHz, DMSO-d6), δ 166.7, 155.9, 
135.2, 131.1, 128.5, 128.4, 128.1, 114.8, 77.2, 62.2, 55.5. 
 
Procedure for the Synthesis of 3-(methoxycarbonyl)oxy-N-(4-methoxyphenyl)-4-
phenyl-2-azetidinone (18a).  
To a solution of β-lactam 17 (500 mg, 1.86 mmol) in 5 ml of freshly distilled CH2Cl2 was 
added NaH (60% suspension in mineral oil, 74.4 mg, 1.86 mmol), and the mixture was 
stirred for 15 min.  Methyl chloroformate (0.17 ml, 2.23 mmol) was then added, and the 
resultant mixture was stirred for 5 h or until TLC indicated the disappearance of starting 
material. The reaction was quenched with a 5% solution of NH4Cl and extracted (3x20 
ml) with CH2Cl2. The combined organic layers were dried over anhydrous MgSO4 and 
purified with column chromatography on silica gel (1:4, EtOAc:hexanes) to give 0.35 g 
(55%) of 17a as a white solid, mp 123-124 °C. 1H NMR (250 MHz) δ 7.35 (s, 5H), 7.28 
(d, J = 8.9 Hz, 2H) 6.81 (d, J = 8.9 Hz, 2H), 5.86 (d, J = 4.8 Hz, 1H), 5.36 (d, J = 4.8 Hz, 
1H), 3.75 (s, 3H), 3.55 (s, 3H).  13C NMR (63 MHz) δ 160.2, 156.6, 154.0, 131.8, 130.2, 
129.0, 128.6, 127.9, 118.8, 114.4, 78.5, 61.3, 55.4, 55.3. 
An analogous procedure was used to prepare β–lactams 18b-e. 
3-(Ethoxycarbonyl)oxy-N-(4-methoxyphenyl)-4-phenyl-2-azetidinone (18b).  
White solid, mp 105-106 °C, 39%. 1H NMR (250 MHz) δ 7.35 (s, 5H), 7.28 (d, J = 9.0 
Hz, 2H) 6.81 (d, J = 9.0 Hz, 2H), 5.83 (d, J = 4.8 Hz, 1H), 5.36 (d, J = 4.8 Hz, 1H), 3.96 
(q, J = 7.1 Hz, 2H), 3.75 (s, 3H), 1.03 (t, J = 7.1 Hz, 3H).  13C NMR (63 MHz) δ 160.2, 
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156.6, 154.0, 131.8, 130.2, 128.9, 128.6, 128.0, 118.8, 114.4, 78.4, 64.7, 61.4, 55.4, 13.9. 
3-(1,1-Dimethylethoxy)carbonyloxy-N-(4-methoxyphenyl)-4-phenyl-2-azetidinone 
(18c).  
White solid, mp 169-170 °C , 98 %. 1H NMR (250 MHz) δ 7.35 (s, 5H), 7.28 (d, J = 8.9 
Hz, 2H) 6.80 (d, J = 8.9 Hz, 2H), 5.74 (d, J = 4.7 Hz, 1H), 5.33 (d, J = 4.7 Hz, 1H), 3.75 
(s, 3H), 1.20 (s, 9H).  13C NMR (63 MHz) δ 160.2, 156.6, 154.0, 131.8, 130.2, 129.0, 
128.6, 127.9, 118.8, 114.4, 78.5, 61.3, 55.4, 55.3. 
3-Phenoxycarbonyloxy-N-(4-methoxyphenyl)-4-phenyl-2-azetidinone (18d).  
White solid, mp 154-155 °C, 21%. 1H NMR (250 MHz) δ 7.42 (s, 5H), 7.34-7.19 (m, 5H), 
6.83 (d, J = 8.9 Hz, 2H) 6.73 (d, J = 8.9 Hz, 2H), 5.89 (d, J = 4.8 Hz, 1H), 5.40 (d, J = 
4.8 Hz, 1H), 3.75 (s, 3H).  13C NMR (63 MHz) δ 159.8, 156.7, 152.0, 150.5, 131.7, 130.1, 
129.5, 129.1, 128.7, 128.2, 126.3, 120.9, 120.7, 118.9, 114.4, 78.9, 61.3, 55.4. 
3-(methoxydithiocarbonyl)oxy-N-(4-methoxyphenyl)-4-phenyl-2-azetidinone (18e). 
White solid, mp 125-126 °C , 15%. 1H NMR (250 MHz) δ 7.32 (s, 5H), 7.29 (d, J = 9.0 
Hz, 2H) 6.81 (d, J = 9.0 Hz, 2H), 6.67 (d, J = 4.8 Hz, 1H), 5.41 (d, J = 4.8 Hz, 1H), 3.75 
(s, 3H), 2.28 (s, 3H).  13C NMR (63 MHz) δ 160.6, 156.6, 131.9, 130.1, 128.9, 128.4, 
128.2, 118.9, 114.7, 81.7, 61.7, 55.5, 18.9. 
 
Procedure for the 3-(Ethoxycarbonyl)oxy-4-phenyl-2-azetidinone (19a).   
To a solution of 18a (330 mg, 1.01 mmol) in 5 ml of CH3CN was added ceric ammonium 
nitrate (1.66 g, 3.03 mmol, 3 eq.) in 5 ml of water. The resultant mixture was stirred for 5 
min, and 10 ml of water was added.  The solution was extracted (3x10 ml) with EtOAc.  
The combined organic layers were washed with 5% NaHSO3, 5% NaHCO3, and dried 
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over anhydrous MgSO4. The solvent was removed under reduced pressure to yield a 
brown oil.  The crude material was purified by flash column chromatography on silica gel 
(1:2 EtOAc:hexanes) to give 150 mg (63%) of 19a as a brown semi-solid. 1H NMR (250 
MHz) δ 7.37-7.28 (m, 5H), 6.90 (bs, 1H), 5.75 (dd, J = 4.7, 2.7 Hz, 1H), 5.03 (d, J = 4.7 
Hz, 1H), 3.52 (s, 3H). 
An analogous procedure was used to prepare β–lactams 19b-e. 
3-(Ethoxycarbonyl)oxy-4-phenyl-2-azetidinone (19b).   
Brown semi-solid, 2%.  1H NMR (250 MHz) δ 7.35-7.31 (m, 5H), 7.02 (bs, 1H), 5.73 (dd, 
J = 4.7, 2.7 Hz, 1H), 5.01 (d, J = 4.7 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 1.22 (t, 3H). 
3-(1,1-Dimethylethoxy)carbonyloxy-4-phenyl-2-azetidinone (19c).  
Brown semi-solid, 72%.  1H NMR (250 MHz) δ 7.35 (s, 5H), 6.67 (bs, 1H), 5.65 (dd, J = 
4.5, 2.8 Hz, 1H), 5.02 (d, J = 4.5 Hz, 1H), 1.19 (s, 9H). 
3-Phenoxycarbonyloxy-4-phenyl-2-azetidinone (19d).  
Brown semi-solid, 78%.  1H NMR (250 MHz) δ 7.43 (s, 5H), 7.30-7.20 (m, 3H), 7.17 (bs, 
1H), 6.72 (m, 2H), 5.78 (dd, J = 4.5, 2.8 Hz, 1H), 5.05 (d, J = 4.5 Hz, 1H). 
3-(methoxycarbonyl)oxy-4-phenyl-2-azetidinone (19e). 
Brown semi-solid, 1%.  1H NMR (250 MHz) δ 7.33 (s, 5H), 6.61 (dd, J = 4.7, 2.5 Hz, 
1H), 6.53 (bs, 1H), 5.03 (d, J = 4.7 Hz, 1H), 2.31 (s, 3H). 
Procedure for Synthesis of N-Methylthio-3-methoxycarboxy-4-phenyl-2-azetidinone 
(20a). 
To a solution of 19a (200 mg, 0.90 mmol) in 5 ml of dry CH2Cl2 was added N-
(methylthio)phthalimide (260 mg, 1.35 mmol) and 3-5 drops of triethylamine. The 
resultant mixture was refluxed overnight.  The solvent was removed under reduced 
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pressure to yield a brown solid.  The brown solid was redissolved in methylene chloride, 
and washed with 1% sodium hydroxide.  The organic layer was dried over magnesium 
sulphate.  The solvent was removed under reduced pressure to yield a brown oil. The 
crude material was purified by column chromatography (1:4 ethyl acetate: hexanes) to 
yield 11.8 mg (5%) of 20a as a white solid. mp 83-84 °C. 1H NMR (250 MHz) δ 7.29-
7.41 (m, 5H), 5.83 (d, J = 5.0 Hz, 1H), 5.03 (d, J = 5.0 Hz, 1H), 3.54 (s, 3H), 2.43 (s, 3H). 
13C NMR (63 MHz) δ 167.3, 153.6, 131.9, 129.2, 128.7, 128.5, 80.1, 65.7, 55.4, 22.1.  
3-(Ethoxycarbonyl)oxy-N-methylthio-4-phenyl-2-azetidinone (20b).  
White solid, mp 71-72 °C, 35%. 1H NMR (250 MHz) δ 7.30-7.40 (m, 5H), 5.80 (d, J = 
4.9 Hz, 1H), 5.02 (d, J = 4.9 Hz, 1H), 3.93 (q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1.01 (t, J = 
7.1 Hz, 3H). 13C NMR (63 MHz) δ 167.4, 153.7, 132.0, 129.1, 128.8, 128.4, 80.1, 65.8, 
64.8, 22.1, 13.8.   
3-(1,1-Dimethylethoxy)carbonyloxy-N-methylthio-4-phenyl-2-azetidinone (20c). 
White solid, mp 81-83 °C, 1%. 1H NMR (250 MHz) δ 7.30-7.39 (m, 5H), 5.69 (d, J = 4.8 
Hz, 1H), 5.01 (d, J = 4.8 Hz, 1H), 2.44 (s, 3H), 1.16 (s, 9H). 13C NMR (63 MHz) δ 167.5, 
151.1, 132.1, 128.9, 128.3, 128.4, 83.3, 79.8, 66.0, 27.2, 22.2.  
N-Methylthio-3-phenoxycarbonyloxy-4-phenyl-2-azetidinone (20d).  
White solid, mp 117-118 °C, 53%. 1H NMR (250 MHz) δ 7.18-7.49 (m, 8H), 6.69 (m, 
2H), 5.87 (d, J = 4.9 Hz, 1H), 5.09 (d, J = 4.9 Hz, 1H), 2.48 (s, 3H). 13C NMR (63 MHz) 
δ 166.8, 151.7, 150.4, 131.8, 129.4, 128.9, 128.6, 126.4, 120.6, 80.5, 66.7, 22.2.  
N-Methylthio-3-methoxydithiocarboxy-4-phenyl-2-azetidinone (20e).  
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White solid, mp 77-78 °C, 1%. 1H NMR (250 MHz) δ 7.28-7.37 (m, 5H), 6.61 (d, J = 4.9 
Hz, 1H), 5.09 (d, J = 4.9 Hz, 1H), 2.45 (s, 3H), 2.31 (s, 3H).  
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Chapter Three 
 
Polymeric Nanoparticles Containing an N-Methylthio β-Lactam 
 
3.1  Introduction 
       In recent years, there has been a rapid growth in the area of drug discovery. This 
has been facilitated by novel technologies such as combinatorial chemistry and high-
throughput screening.1,2,3  These novel approaches have led to numerous drug 
candidates within very short periods of time compared with the conventional drug 
discovery method. Many of these analogs show promising biological activity in vitro 
and in vivo. However, most of them do not progress to commercialization because of 
the problems of unwanted cytotoxicity (no targeting and no controlled release), very 
poor water solubility and, consequently, low bioavailability. These problems are 
closely related to optimal drug delivery systems in the human body which is why 
research on drug delivery systems has been and remains a hot topic in drug 
discovery.4,5 
       Fig. 3-1 shows a hypothetical comparison of the concentration of drug found in 
the plasma as a function of time following conventional drug release versus 
controlled drug release by oral drug administration.  As can be seen in Fig. 3-1, the 
conventional oral drug administration does not provide ideal pharmacokinetic profiles, 
especially for drugs which display high toxicity and/or narrow therapeutic periods of 
time. For such drugs, if they can be conjugated to an optimal drug delivery system, 
the ideal pharmacokinetic profile can be achieved wherein the drug concentration 
reachs therapeutic levels without exceeding the maximum tolerable dose, and 
maintains these concentrations for extended periods of time until the desired 
therapeutic effect is reached. Therefore, optimizing drug delivery is a good answer for 
treatments that involve highly cytotoxic drugs such as certain anticancer agents, so 
that toxic side effects and damage to healthy tissues are minimized. 
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             Fig. 3-16 Comparison of  conventional and controlled release profile
 
 
       In recent years, significant effort has been devoted to developing micro or nano-
size microsphere technology for drug delivery.7,8,9 These microspheres offer a 
suitable means of delivering small molecular weight drugs, as well as 
biomacromolecules such as proteins, peptides or genes by either sustained or targeted 
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delivery to the tissue of interest. This technology focuses on formulating  therapeutic 
agents in biocompatible or biodegradable polymeric nanocomposites such as 
nanoparticles or nanocapsules. Since these systems are often polymeric and 
submicron in size, they have multiple advantages in drug delivery. These systems in 
general can be used to provide cellular or tissue delivery of drugs, to improve oral 
bioavailability, to sustain drug/gene effect in target tissue, to enhance the water 
solubility of drugs for intravascular delivery, and to improve the stability of 
therapeutic agents against enzymatic degradation (nucleases and proteases).7 
However, the majority of current technologies are focusing on controlled or sustained 
release systems via drug encapsulation methods using biodegradable polymeric 
nanoparticles, even though the nanometer-size ranges of these delivery systems offer 
certain distinct advantages for drug delivery. Therefore, if nanoparticles can penetrate 
deep into tissues and through endocytosis are taken up efficiently by the cells10, this 
allows efficient delivery of therapeutic agents to target sites in the body. Also, by 
modulating polymer characteristics, one can control the release of the drug from 
nanoparticles to achieve a desired therapeutic level in target tissue for optimal 
therapeutic effects. Further, nanoparticles can be delivered to target sites either by 
localized delivery using an enhanced permeation and retention (EPR) effect11, 12 or by 
targeted delivery through conjugation to a biospecific ligand which could direct them 
to the target tissue or organ.7  
       In this research, microemulsion polymerization was done in aqueous solution to 
form hydrophilic polymeric nanoparticles containing a highly water-insoluble solid 
antibiotic, an N-methylthio β-lactam. N-Methylthio β-lactams are a new family of 
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potent antibacterial compounds that selectively inhibit the growth of methicillin-
resistant Staphylococcus aureus (MRSA). These drugs tend to be insoluble in water, 
and it was hoped that this method could enhance water solubility and bioavailability 
of these drugs. In addition, the antibacterial activity of these resulting polymeric 
nanoparticles was investigated against MRSA strains. 
       The synthesis of  N-thiolated β-lactam acrylic monomers for radical 
polymerization, and the conjugation of these acrylic monomers into a polymeric 
nanoparticle using a novel microemulsion polymerization method, are described 
herein. We also describe the characterization of the polymer, its antibacterial 
properties, and the relationship that may exist between antibacterial activity, % drug 
content, and particle size. 
       Finally, the preparation and the characterization of a fluorescence-active 
nanoparticle is reported in chapter four for diagnostic purposes such as elucidating the 
biological mode of action, acting as a biological sensor and biological imaging. 
 
3.2  Conventional Microemulsion Polymerization 
       Microemulsion polymerization was first reported in the early 1980’s. This 
process can produce transparent or translucent polymeric microlatexes with particle 
diameters of 50nm or higher. Over 45% of all industrial polymers have been prepared 
by using emulsion polymerization. The main advantages of this process are: a) water 
is used as the sole solvent, b) the viscosity of emulsion is relatively low and 
independent of the polymer molecular weight, and c) high molecular weight polymers 
with a narrow weight distribution can be produced in a controlled environment. 
13, 14  
 57
Therefore, this emulsion polymerization is bringing about the renaissance in the 
industrial polymer area.  
       A conventional emulsion polymerization consists of dispersing a water insoluble 
acrylic monomer phase, which is the low viscosity liquid phase, in an aqueous phase 
with the aid of surfactants. Polymerization is then brought about by free radical 
initiation in the water phase. The polymer formed is stabilized within the emulsion by 
absorption onto surfactants to form a protective colloid form as the polymerization 
proceeds. The resultant products are homogeneous and relatively stable emulsified 
polymeric microspheres. The surfactant is a hydrocarbon chain with one end being 
hydrophobic and the other hydrophilic. If the concentration of surfactant is high 
enough, the hydrophobic ends of several surfactants form aggregates known as 
micelles. The surfactant serves as a stabilizer for the polymer particles and the 
monomer droplets. Therefore, the hydrophobic ends will attach to the particles while 
the hydrophilic ends will remain in the water phase. The charges on these surfactants 
form what is known as an electrical double layer which prevents the particles from 
coagulating. In other words, the emulsifier serves to keep the particles suspended in 
the water. The micelles can also be the location of particle nucleation. The monomer 
is present in the reaction mixture in the form of large droplets. These droplets act as  
reservoirs of the monomer. The monomer in the droplets can diffuse through the 
water phase and into the micelles. When the initiator is added to the reaction mixture 
it dissociates into two radicals in the presence of heat. The initiator radicals are very 
reactive towards any monomer in the water phase. The monomer in the water phase 
continues to add to the radical until the chain grows long enough such that it is no 
longer soluble in water. The oligomeric radical chain (multiple monomeric units) is 
now hydrophobic enough to enter a polymer particle or to enter a micelle to nucleate 
a new particle. Thus, the conventional emulsion polymerization will occur in three 
stages. The first stage involves the nucleation (birth) of polymer particles. This can 
occur by either micellar or homogeneous nucleation. The second stage involves the 
growth of the particles until the monomer droplets disappear. The third and final stage 
begins with the disappearance of the monomer droplets and continues until the end of 
the reaction (Fig. 3-2).15, 16  
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Fig. 3-2 Schematic representation of an emulsion polymerization system15
        
       Conventional emulsion polymerization methods are difficult to use for the 
preparation of polymeric microspheres for drug delivery systems, since most drugs 
are either partially or completely insoluble in water, and as such cannot form the 
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liquid droplet in the emulsion polymerization process. The acrylic part on the original 
chemical structure of the drug has to be introduced synthetically for free radical 
polymerization without losing activity. Therefore, the challenge is to prepare 
polymeric microspheres for drug delivery systems using a new emulsion 
polymerization method which can overcome these problems. 
 
3.3  Synthesis of C3-Acryloyl N-Methylthio β-Lactam as a Key Monomer 
       The acrylation of N-methylthio β-lactams is required for microemulsion 
polymerization using free radicals. Acrylation can be accomplished at either the C3 or 
the C4 position of the β-lactam. In this study, the C3-acrylation of the β-lactam was 
studied. The synthesis of  C3-acryloyl N-methylthio β-lactam is summarized in 
Scheme III-1. The key step is to introduce the acryloyl group at the C3-position, 
which can then participate in the radical copolymerization with the other acrylic co-
monomer.  
       2-Chlorobenzaldehyde (21) was coupled with p-anisidine, to give imines 22. 
Staudinger coupling of acetoxyacetyl chloride with imine 22 gave C3-acetoxy N-aryl 
protected β-lactam 23. Hydrolysis of acetoxy group under basic conditions gave the 
C3-free hydroxyl β-lactam 24.  Acrylation of free hydroxyl β-lactam 24 with acryloyl 
chloride gave C3-acryloyl N-aryl protected β-lactam 25. Dearylation of β-lactam 25 
with ceric ammonium nitrate gave N-dearylated β-lactam 26, followed by 
methylthiolation with N-methylthio- phthalimide affords C3-acryloyl N-methylthio β-
lactam 27 which is a white solid, mp 92-93 oC . The 1H NMR spectra of C3-acryloyl 
N-methylthio β-lactam 27 is displayed in Fig. 3-3. 
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Fig. 3-3 1H NMR Spectra of C3-acryloyl N-methylthio β-lactam 
 
3.4 Main Components for Microemulsion Polymerization 
       The microemulsion polymerization used to prepare the polymeric nanoparticles  
consists of four major components: 1) acrylic drug monomer, 2) acrylic co-monomer, 
3) surfactant, and 4) deionized water. The selection and requirement of each of these 
components are described below.  
 
3.4.1 Choice of Drug Monomer  
       The drug monomer needs to contain three essential parts; the first one is the drug 
itself, the second one is the acrylic moiety for radical polymerization and the third 
one is the linker that connects the drug with the acrylic moiety such that it can break 
down biologically or enzymatically. The general features are shown in Fig. 3-4.  
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                                      Fig. 3-4 Structure of drug monomer 
 
       A wide variety of drugs (antibacterial, antiviral, antifungal and anticancer agents, 
etc.) can potentially be used in this method, including those which have little or no 
water solubility as well as those that have good water solubility.       
       A variety of acrylic monomers can conceivably be synthetically coupled with a 
drug containing a functional group such as a carboxylic acid, an amine or an alcohol. 
Examples of such monomers include acryloyl chloride, methacryloyl chloride, acrylic 
acid, maleic acid, itaconic acid, crotonic acid, N-methylol acrylamide, acrylonitrile, 
2-hydroxyethyl acrylate, 2-hydroxypropyl acrylate, 2-hydroxyethyl methacrylate 
       Modified acrylamide, modified methacrylamide, (PEG) modified acrylate, amino 
acid oligomeric acrylate etc. also can be possibly used for specific controlled release 
system since the amino acid oligomer which is active for a specific enzyme can be 
selectively cleaved under certain biological conditions.  
 
3.4.2 Choice of Co-monomer  
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       Commercial acrylic or vinyl monomers can be used as the co-monomers. The 
choice of co-monomers is entirely dependent on the chemical and physical properties 
of the drug monomer. It is a critical that the commercial or synthetically modified 
acrylic monomers are able to play two roles in the polymerization process: (1) as the 
co-monomer for the radical emulsion polymerization and (2) as the solvent for 
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dissolving the synthetically modified drug monomers in order to make homogeneous 
liquid phase. Therefore, it is very important to find a specific acrylic co-monomer that 
matches a specific drug monomer, and this is accomplished by trial and error. 
Fortunately, there are many acrylic monomers available commercially and/or 
synthetically: acrylonitrile, acrylic acid, maleic acid, methyl acrylate, ethyl acrylate, 
butyl acrylate, 2-ethylhexyl acrylate, methoxyethyl acrylate, dimethylamino acrylate, 
methacrylic acid, methyl methacrylate, ethyl methacrylate, butyl methacrylate, 
isobutyl methacrylate, 2-ethyl hexyl methacrylate, lauryl methacrylate, stearic 
methacrylate, dimethyl amino methacrylate, allyl methacrylate, 2-hydroxyethyl 
acrylate, 2-hydroxypropyl acrylate, 2-hydroxyethyl methacrylate, modified 
acrylamide, modified methacrylamide, glycidyl acrylate, styrene, vinyl acetate, vinyl 
toluene, and all synthetically modified acrylics can be used. 
 
3.4.3 Choice of Surfactant 
       The surfactant that is used in emulsion polymerizations has two ends of different 
solubility. One end, termed the tail, is a long hydrocarbon that is soluble in nonpolar, 
organic compounds. The other end, the head, is often a hydrophilic functional sodium 
or potassium salt, which is water soluble. The water soluble salt can be the salt of a 
carboxylic acid or sulfonic acid. The technical term for the chemical display of "dual 
personalities" is amphipathic.  
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The selection of emulsifiers (or the surfactants) is very important for a 
successful formulation as it can control many of the properties of emulsion polymers. 
There is a critical concentration below which an emulsifier will not form micelles. 
The minimum level required for micelle formation is known as the critical micelle 
concentration (CMC). Emulsifiers are classified according to the ionic type of the 
hydrophilic group, ionic or non-ionic. Ionic emulsifiers generally have a lower CMC 
than non-ionic emulsifiers and they provide low particle size emulsions. However, 
there is a problem with long term storage of these compounds.  In the case of non-
ionic emulsifiers, they need higher CMC level because of their low water solubility so 
that it leads to the formation of small aggregates or grainy emulsions. However, once 
the particles are formed they are very stable in aqueous systems. As a result of these 
advantages and disadvantages, ionic/non-ionic emulsifier mixtures can be employed 
in emulsion polymerization. Therefore, the factors for selecting the emulsifiers are 
totally dependent on the chemical or physical properties of the applied drug monomer 
and co-monomer, radical initiator and aqueous system.  
As the choice of surfactants, anionic, cationic and nonionic surfactants such as 
lauryl alcohol (+6EO), nonyl phenol (+10EO, +15EO, +30EO), sodium lauryl 
sulphate, sodium lauryl sulphate (+2EO, +4EO), sodium dodecylbenzenesulphonate,         
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sodium dioctyl sulphosuccinate, polyvinyl alcohol, polyol, unsaturated and saturated 
fatty acid sodium and potassium salts, and synthetically modified PEG surfactants can, 
in principle, be used. 
 
3.4.4  Choice of Radical Initiator  
The initiator must be water soluble and the free radicals have to be generated 
thermally or by use of an oxidation-reduction (or redox) couple. The major initiators 
used in emulsion polymerization are persulphates.  
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Even though the initiating efficiency and the half life of persulphates vary, 
ammonium persulphate is preferred in practice because of its better solubility. 
Hydroperoxides are often used particularly as a post reaction initiator to kill the 
unreacted monomers after emulsion polymerization. The rate of free radical 
generation increases with temperature, and it is normal to employ reaction 
temperatures of 60-90oC when using thermal generation techniques. However, when 
redox couples (thiosulphates, metabissulphites and hydrosulphides) are employed, the 
rate of free radical generation is increased to that provided by thermal generation at 
the same temperature. Therefore, when using redox couples, reaction temperatures 
can be as low as 30oC.  Possible free-radical initiators for use in the initiating step of 
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polymerizations include: peroxides; persulphates; alkyl hydroperoxides; persulphates 
with sodium, ammonium and potassium; thiosulphates; metabisulphites; and 
hydrosulphides.   
 
3.4.5  Choice of Aqueous Media 
       The aqueous media is the major part of the emulsion polymerization. The ions or 
metals in the aqueous media can act as a radical scavenger. Therefore the aqueous 
media used has to be either de-ionized water or nano-pure water for biological 
purposes. It is sometimes necessary to use a buffer solution depending on the 
surfactant and the particle stabilization. 
 
3.5 The Preparation of Polymeric Nanoparticles Using Microemulsion 
Polymerization 
 
       Polymeric nanoparticles of N-methylthio β-lactam were prepared by a novel 
microemulsion polymerization technique described in Scheme III-2. The key point of 
this method was the complete dissolution of the solid drug monomer in a commercial 
acrylic monomer at elevated temperature, followed by its dispersion into an aqueous 
media containing a surfactant for the stabilization of the suspension. Therefore, it is 
very critical to get a homogeneous liquid mixture. In the first example studied, C3-
acryloyl N-methylthio β-lactam 21 and ethyl acrylate were combined at 70oC. The 
mixture was then dispersed into an aqueous media containing a surfactant, sodium 
lauryl sulphate, to allow the formation of droplets with vigorous stirring until a milky 
suspension was formed. The emulsion radical polymerization then was launched by 
adding the initiator, potassium persulfate, at 70oC to afford the polymeric 
nanoparticles as a milky colloidal suspension (Fig. 3-5).  
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                                      Fig. 3-5 β-lactam polymeric emulsion 
 
       Other anaologs were prepared by emulsion polymerization by varying the ratios 
of monomers and reaction conditions. The formulations of polymerization are 
summarized in Table 3-1. 
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entry    mole ratio            monomers(mg)            surfactant (mg)     initiator(mg)        water (ml)     rxn. temp.(oC)
         
         EA1 : β-lactam1    β-lactam1      EA1           lauryl sulphate1    persulphate1
           
           
  1         EA homo            0               1000                    20                       5.0                      5.0                  60
  22          20 : 1             100                700                    16                       4.0                      4.0                  70
  32          13 : 1             100                456                    12                       3.0                      2.8                  70 
  42          10 : 1             100                350                      9                       2.5                      2.3                  70
  52            7 : 1             100                245                      7                       1.8                      1.8                  70
  62            5 : 1             100                175                      6                       1.5                      1.4                  70
  72         2.5 : 1             100                  88                      3                       0.8                      0.7                  70
  
  1 EA:ethyl acrylate, β-lactam: C3-acryloyl N-methylthio β-lactam, lauryl sulphate: sodium salt, 
     persulphate: potassium salt
  2 The scale was varied several times based on volume.
Table III-1 Formulation of Microemulsion Polymerization
 
 
3.6 Characterization of Emulsion  
3.6.1 Scanning Electron Microscopy (SEM)  
The morphology and the particle size of the emulsified particles were 
examined by Scanning Electron Microscopy (SEM). The sample of nanoparticles was 
prepared on the silicon wafer by air blowing and then was coated with gold sputter 
under high vacuum. The gold-coated nanoparticles were then observed by SEM 
(Hitach S800). The SEM images of the copolymeric nanoparticles for the β-lactam 
and ethyl acrylate are shown in Fig. 3-6 through Fig. 3-12.  
The SEM image of the polymeric nanoparticles for homo poly (ethyl 
acrylate): Fig. 3-6 shows the polymeric nanoparticles deformed by the electron beam 
of SEM because of the low Tg, -23 oC of homo poly(ethyl acrylate). The SEM images 
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of the copolymeric nanoparticles, (20:1 through 2.5:1 for ethyl acrylate: β-lactam) 
show that the particles have microspherical morphology with the particle size 
distribution of 40 nm to 150 nm in diameter.  It is very interesting that the 7:1 
copolymeric nanoparticles have the smallest particle size distribution (40-80 nm), 
while the 2.5:1 copolymeric nanoparticles had a  uniform particle size of 70 nm. The 
particle size distribution of the copolymeric nanoparticles for the β-lactam and ethyl 
acrylate, determined by SEM  analyses, are summarized in Fig. 3-13. 
 
 
 
         Fig. 3-6 SEM picture for homo ethyl acrylate polymeric nanoparticles 
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                                                                         (a) 
 
(b) 
Fig. 3-7  SEM pictures for 20:1 copolymeric nanoparticles which has  particle 
size, 60-150 nm; (a) and (b) 
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 (a) 
 
(b) 
Fig. 3-8  SEM pictures for 13:1 copolymeric nanoparticles which has  particle 
size, 60-150 nm; (a) and (b) 
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 (a) 
 
(b) 
Fig. 3-9  SEM pictures for 10:1 copolymeric nanoparticles which has  particle 
size, 100-130 nm; (a) and (b) 
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 (a) 
 
(b) 
Fig. 3-10  SEM pictures for 7:1 copolymeric nanoparticles which has  particle 
size, 40-80 nm; (a) and (b) 
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(a) 
 
(b) 
Fig. 3-11  SEM pictures for 5:1 copolymeric nanoparticles which has  particle 
size, 130-150 nm; (a) and (b) 
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(a) 
 
(b) 
Fig 3-12.  SEM pictures for 2.5:1 copolymeric nanoparticles which has  particle 
size, 70nm; (a) and (b) 
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Fig. 3-13  Particle size distribution of β-lactam copolymeric nanoparticles
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3.6.2 Coalescing Process 15,16
       For further characterization of β-lactam copolymeric nanoparticles, thin films 
were prepared by a coalescing process. The polymeric particles experience an 
irreversible structural change during film formation. The particles, upon evaporation 
of water, come into contact, fuse and form a uniform film through a process called 
coalescense. In general it is assumed that the film formation can be separated into the 
following three stages:  
Stage 1: Water evaporates slowly and thus polymer particles become concentrated. 
Stage 2: The particles deform to form a dense closed packing. 
Stage 3: The fully coalesced particles produce a uniform film. 
The coalescing process is summarized in Fig. 3-14. 
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Fig. 3-14 Representation of the coalescing process 15
3.6.3   Determination of Solid Content (%) 
       The measurement of the non-volatile solid (β-lactam) content in polymer is 
critical for determining the amount of the drug in the polymeric emulsion. The solid 
content is defined as the weight percent of the non-volatile solid among total weight 
of the emulsion. The weight percent of polymer in the emulsion can be calculated 
quantitatively after film formation via the coalescence process. The calculation 
method is described in Fig. 3-15. All solid content measurements were done in 
triplicate and the average value is reported. 
Al foil
only
Al foil
+
sample
solution
Al foil
+
dry 
polymer
A B C
1. A – B =  The weight of sample solution
2. A – C =  The weight of dry polymer
Solid Content (%) = (A – B) / (A – C) x 100 
      
Fig. 3-15 Determination of solid content (%) 
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3.6.4  1H NMR Spectra Analysis 
       1H NMR spectroscopy is a very powerful tool to analyze chemical structure of 
organic molecules. It can also be used to determine the mole ratio of each of the 
monomeric units, (β-lactam and ethyl acrylate) in copolymers. Fig. 3-16 shows the 
cumulated 1H NMR spectra for the dry films obtained by coalescing the nanoparticle 
emulsions of homopoly(ethyl acrylate) and six different copolymers of the β-lactam 
and ethyl acrylate. Signals at (d) 2.6, (b) 5.6 and (c) 6.1 ppm are assigned to S-CH3, 
C3-H and C4-H on β-lactam respectively. The signal at (a) 4.0 ppm is assigned to the 
methylene proton of ethyl acrylate. The olefin protons of acrylate in the range of  5.6-
6.1 ppm do not show in the spectrum. That indicates that all of the monomeric β-
lactam acrylate and ethyl acrylate was converted to polymeric particles. In addition, 
the composition of the polymeric nanoparticles can be determined by 1H NMR 
spectroscopy as mentioned. The mole ratio of β-lactam and ethyl acrylate in the 
copolymer was determined from the peak integration of the methylene proton (a) of 
ethyl acrylate and a proton of C3 (b) or C4 (c) on the β-lactam respectively. Fig. 3-16 
also shows the solid content of each of the polymers. The β-lactam loading amount 
on the each polymers can be calculated quantitatively based on these parameters, 
based on the mole ratio of each monomers, the loading volume and the solid content.  
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Fig. 3-16  1H NMR Spectra, the mole ratio and the solid content of β-lactam and 
ethyl acrylate copolymers 
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3.7 Biological Activity Against MRSA 
3.7.1 Initial Testing 
       The N-methylthio β-lactam-conjugated polymeric nanoparticles and their 
coalesced plastic films were tested for antibacterial activity using the Kirby-Bauer 
method of disc diffusion on agar plates. The 7:1 (ethyl acrylate : lactam) copolymeric 
nanoparticles and their plastic film as well as the homo poly(ethyl acrylate) 
nanoparticles and their plastic film, were also tested against a strains of methicillin-
resistant Staphylococcus aureus (MRSA). Fig. 3-17 shows the results of this testing. 
It is obvious that the plastic films of the 7:1 copolymer and the homo polymer, as 
well as the homo poly(ethyl acrylate) nanoparticles have no activity against MRSA. 
However, the 7:1 copolymeric nanoparticles surprisingly have strong activity against 
MRSA. That means the film polymers, whether they contain the drug or not, have no 
activity, and the nanoparticles that do not bear a drug, also have no activity. This 
initial result indicates that further research should be focused on nanoparticles having 
the attached β-lactam drug.  
7:1 acrylate:lactam 
nanoparticles 
7:1 acrylate:lactam 
dry film* 
(with drug) (with drug) 
homo polyacrylate 
homo polyacrylate nanoparticles 
dry film* (without drug) 
(without drug) 
*Dry film was dissolved in DMSO for testing. 
Fig. 3-17 Initial antibacterial testing of nanoparticles and polymer 
films against MRSA 652 
 
 
 
3.7.2 Antibacterial Testing of Homo Poly(ethyl acrylate) Nanoparticles 
(Without N-Methylthio β-Lactam) 
 
       The antibacterial testing of homo poly(ethyl acrylate) nanoparticles was 
performed as a control experiment. A sample of the nanoparticle suspension was 
tested against MRSA on an agar plate, with increasing disk loading amounts from 20 
µl to 100 µl. No activity was observed even at 100 µl of disk loading (Fig. 3-18). This 
result is consistent with that of the initial testing showing that the polymeric 
nanoparticle which has no drug, has no activity. Therefore, the focus next was to the 
test the antibacterial activity of the nanoparticles that do contain the N-methylthio β-
lactam drug.  
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         Fig. 3-18 Antibacterial testing of homo poly(ethyl acrylate) nanoparticle 
against MRSA  
 
 
3.7.3 Antibacterial Testing of Lactam-containing Nanoparticles Against MRSA 
 
       Nanoparticles containing the N-methylthio β-lactam were evaluated for 
antibacterial activity against ten MRSA strains by Kirby-Bauer of disc diffusion on 
agar plates. Six different samples of the nanoparticle emulsions were tested, varying 
in the relative amounts of drug to ethyl acrylate used to prepare the particles (20:1 to 
2.5:1). Table 3-2 displays the observed zones of inhibition for the nanoparticles. It is 
very interesting that all samples containing the N-methylthio β-lactam are active 
against the MRSA strains as well as the non-resistant strain of S. aureus. In addition, 
the strongest bioactivity was observed for the 7:1 (acrylate:lactam) nanoparticles, 
which have the smallest particle size distribution, 40-80 nm. Therefore, these facts 
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indicate that research should be focused on the biological mode of action of these 
conjugated nanoparticles, and the relationship of particle size to biological activity. 
The images of the agar plates used to test against MRSA and S. aureus  are displayed 
in Fig. 3-19 through Fig. 3-29. 
 
strains               homo EA     20 : 1          15 : 1          10 : 1            7 : 1              5 : 1             2.5 : 1
MRSA 652               0              14               11                 18                23                 16                 17
           653               0              15               13                 24                28                 24                 24
           654               0              14               12                 15                23                 17                 16
           655               0                0               11                 18                22                 17                 15
           656               0              12               15                 18                23                 17                 18
           657               0              12               12                 18                24                 17                 16
           658               0                0               12                 17                24                 18                 16
           659               0                0               14                 16                22                 17                 17
           919               0                0               11                 17                22                 17                 17
           920               0                0               12                 16                23                 18                 16                                 
S. aureus 849          0              13               16                 18                24                  20                19
nanoparticles having monomer ratio of EA* : β-lactam
Table III-2. Zones of inhibition obtained from agar well diffusion experiments using 20 µl
of the emulsified suspension of the test nanoparticles. The values correspond to the
diameters in mm for the zone of growth inhibition appearing around the well after 24 hours. 
Staphylococcus aureus and β-lactamase-producing strains of methicillin-resistant
Staphylococcus aureus (labeled MRSA USF652-659) were obtained from a clinical testing
laboratory at Lakeland Regional Medical Center, Lakeland, FL or from ATCC sources.
* ethyl acrylate (EA)
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7:1
5:1 20:1
2.5:1
 
               Fig. 3-19 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 652 (ratios of ethyl acrylate : lactam indicated) 
 
                           
homo
2.5:1
5:1 20:1
7:1
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                           Fig. 3-20 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 653 (ratios of ethyl acrylate : lactam indicated) 
  
2.5:1
homo
5:1 20:1
7:1
 
                     Fig. 3-21 Antibacterial testing of drug-embedded nanoparticles   
against MRSA 654 (ratios of ethyl acrylate : lactam indicated) 
  
2.5:1
homo
7:1
5:1 20:1
 
               Fig. 3-22 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 655 (ratios of ethyl acrylate : lactam indicated) 
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2.5:1
homo
7:1
5:1 20:1
 
                  Fig. 3-23 Antibacterial testing of drug-embedded nanoparticles 
                against MRSA 656 (ratios of ethyl acrylate : lactam indicated) 
 
2.5:1
homo
7:1
5:1 20:1
 
                           Fig. 3-24 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 657 (ratios of ethyl acrylate : lactam indicated) 
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2.5:1
 
               Fig. 3-25 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 658 (ratios of ethyl acrylate : lactam indicated) 
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2.5:1
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                     Fig. 3-26 Antibacterial testing of drug-embedded nanoparticles     
against MRSA 659 (ratios of ethyl acrylate : lactam indicated) 
homo
7:1
5:1 20:1
2.5:1
 
                           Fig. 3-27 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 919 (ratios of ethyl acrylate : lactam indicated) 
 
                                 
                        Fig. 3-28 Antibacterial testing of drug-embedded nanoparticles 
against MRSA 920 (ratios of ethyl acrylate : lactam indicated) 
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7:1
5:1
20:1
2.5:1
 
                     Fig. 3-29 Antibacterial testing of drug-embedded nanoparticles  
against S. aureus 849 (ratios of ethyl acrylate : lactam indicated) 
 
 
3.8 Antifungal Testing of Nanoparticle Emulsions 
       In the previous section the 7:1 (acrylate:drug) nanoparticles showed the most 
promising antibacterial activity against MRSA strains. Thus, it is very meaningful to 
extend the testing of these emulsions to fungus, because N-methylthio β-lactams have 
previously been found (Marci Culbreath, unpublished results) to have activity against 
fungal strains. The antifungal testing of these nanoparticles was performed by Kirby-
Bauer disc diffusion on agar plates against eight genera of fungi. Table 3-4 displays 
the zones of inhibition observed nanoparticles. It is very interesting that nanoparticles 
are very active against all of the fungal strains, with antifungal activity of the N-
thiolated lactam (1 µg) in the nanoparticles being similar to that of the standard, 
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clotrimazole (50 µg). That means the 7:1 (acrylate:lactam) nanoparticles are fifty 
times more potent than clotrimazole. This indicates that drug containing  
nanoparticles are promising leads to new antifungal agents as well as an antibacterial 
antibiotics. 
 
26                                                     26               20
20               24                                  22               20
19               20               16               18               14
21               23               20               21               37
24               27               29               27               27
31               32               32               32               25
19               20               22               20               32
22               23               23               23               24
C. albicans
C. tropicalis
C. glabrata
C. kefyr
C. krusei
C. lusitaniae
C. parapsilosis
C. utilis
average
standard
clotrimazole
( 50 µg)1st 2nd 3rd
nanoparticlesfungal
strains*
Table III-4. Zones of inhibition obtained from agar well diffusion experiments
using 20 ml of 7:1 (ethyl acrylate:lactam) nanoparticle emulsion. This
corresponds to 1 mg of active drug in the particle. The values correspond to the 
diameters in mm for the zone of growth inhibition appearing around the well
after 48 hours.
 
 * Fungi were chosen on the basis of their potential pathogenicity. C. albicans and C. tropicalis 
were donated by Dr. Ray Widen from the University of South Florida, School of Medicine. C. 
glabrata (ATCC 15126), C. krusei (ATCC 14243), C. keyfr (ATCC 20409), C. parapsilosis 
(ATCC 22019), C. lusitaniae (ATCC 34449) and C. utilis (ATCC 29950) were obtained 
commercially. 
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3.9 Discussion 
          Nanoparticles comprised of poly(ethyl acrylate) were made by a novel 
microemulsion polymerization procedure. This method has the advantage over 
conventional emulsion polymerization methods because a solid co-monomer (β-
lactam drug) is utilized. This method may open a new area in drug delivery and help 
to solve the main problems in drug discovery: unwanted cytotoxicity, water 
insolubility and low bioavailability of drug.  The core feature of this method, as 
mentioned in section 3.5, is to make a homogeneous solution of monomeric 
substances at elevated temperature (60 oC or 70 oC) and to disperse this mixture in 
aqueous media containing a suitable surfactant (to stabilize the nanoparticles). 
Radical polymerization within these pre-formed particles then ensues to make the 
nanospherical polymers. 
       A water-insoluble solid antibiotic, N-methylthio β-lactam, was synthetically 
converted to a C3-acryloyl β-lactam derivative and its homogenized into a liquid state 
with ethyl acrylate as a co-monomer was generated at 70 oC. The  N-methylthio β-
lactam-containing nanoparticles were then prepared by free radical microemulsion 
polymerization after dispersing in an aqueous phase. Thus, it was demonstrated that 
the N-methylthio β-lactam could be incorpoated as a monomer to generate a new N-
methylthio β-lactam-containing nanoparticle. It is likely that this new method can be 
applied to many other water-insoluble solid drugs (or those having high viscosity).        
      The N-methylthio β-lactam-containing nanoparticles were subjected to 
antibacterial testing against various MRSA strains. Fig. 3-30 displays a comparison of 
  
homo 20:1 13:1 10:1 7:1 5:1 2.5:1
5
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35
Pen G Vancomycinmonomer
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(20 µl)
0.00 µg 
(20 µl)
0.50 µg 
(20 µl)
0.66 µg 
(20 µl)
1.02 µg
(20 µl)
0.91 µg
(20 µl)
1.76 µg 
(20 µl)
20 µg20 µg 20 µg
acrylate and β-lactam emulsified copolymers
S. aureus 849
standards
MRSA MRSA MRSA MRSA MRSA MRSA MRSA MRSA MRSA
0
 
Fig. 3-30 Comparison of antibacterial activities of N-thiolated  β-lactam-
containing emulsified nanoparticles. 
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antibacterial activities for each of the different emulsified nanoparticles to penicillin 
G (Pen. G), vancomycin, and C3-acryloyl β-lactam 27 as standards. It also shows the 
actual amounts of drug contained within 20 µl of the nanoparticle emulsion tested.        
       It is apparent that all N-methylthio β-lactam containing nanoparticles are active 
against MRSA strains as well as the non-resistant strain, S. aureus 849.  Their activity 
trend appears to increase gradually as the portion of drug (β-lactam) increase from 
20:1 (ethyl acrylate:antibiotic)to the 7:1 and reachs the maximum at the 7:1.  
However, the bioactivity decreased for particles having an ethyl acrylate:lactam ratio 
of 5:1, and the activities of the 5:1 and 2.5:1 nanoparticles are similar even though the 
portion of drug (β-lactam) is increased. Therefore, the result indicates that the 
antibacterial performance of N-methylthio β-lactam containing nanoparticles is 
enhanced dramatically over that of the free antibiotic, and the 7:1 (ethyl 
acrylate:lactam) nanoparticles show the best activity. 
       The comparison of antibacterial activity of the N-methylthio β-lactam containing 
emulsified nanoparticles and the standards: penicillin G (Pen. G), vancomycin, and 
C3-acryloyl β-lactam 27 against MRSA, shows that the emulsified nanoparticles have 
similar and/or better activities at very low drug amount compared with those of 
standards. However, the activity of 7:1 (ethyl acrylate:lactam) nanoparticles are better 
even at low drug amount (0.91 µg) compared with that of vancomycin (20 µg). It is 
likely that the activity of the 7:1 nanoparticles is over 20 times more than that of 
vancomycin. 
        Fig. 3-31 and Fig. 3-32 display a comparison of  the antibacterial activities of the 
2.5:1, 5:1, 7:1 and 10:1 (ethyl acrylate:lactam) nanoparticles against MRSA and non-
resistant S. aureus with decreasing sample loading volume (20 µl to 12 µl). The 
amount of sample was proportional to the bioactivity. However, the N-methylthio β-
lactam containing nanoparticles still possess good activities even at 12 µl of loading 
volume. Most notably the 7:1 copolymeric nanoparticles still show the strongest 
activity.  
20 µl 18 µl 16 µl 14 µl 12 µl
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m
)
0
5
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2.5:1
disk loading amount (µl of emulsion)
           Fig. 3-31 Bioactivity of polymeric nanoparticles as a function of disk           
loading amounts (MRSA 653) 
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         Fig. 3-32 Bioactivity of polymeric nanoparticles as a function of disk    
loading amounts for S. aureus 849 
 
       Fig. 3-33 displays antibacterial activity of the 7:1 nanoparticles as the sample 
loading volume is decreased from 20 µl to 2 µl against MRSA and S. aureus. 
Surprisingly, the activity of the 7:1 nanoparticles for MRSA maintained a strong level 
of potency (over 20 mm zone of inhibition) until the volume was reduced to 6 µl 
(0.27 µg) and even at 2 µl (0.09 µg, 14 mm in the zone of inhibition). In addition, 
against S. aureus the particles also show a good level of antibiotic activity until the 
loading amount is reduced to 6 µl (0.27 µg, 16 mm zone of inhibition).  
       The relative antibacterial activities for 7:1 (ethyl acrylate:lactam) nanoparticles, 
Pen G, vancomycin, and C3-acryloyl N-methylthio β-lactam 27 were also evaluated at 
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1 µg since 20 µl of volume for the 7:1 nanoparticles contains approximately 1 µg of 
β-lactam.   
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Fig. 3-33 Bioactivity of 7:1 copolymeric nanoparticles as a function of decreasing 
disk loading amounts 
                             
        Fig. 3-33 shows a comparison of relative antibacterial activities against MRSA. 
It is obvious that Pen G and C3-acryloyl N-methylthio β-lactam have no activity and 
vancomycin is very weak at 1 µg of drug amount level. However, the 7:1 (ethyl 
acrylate:lactam) nanoparticles show very strong activity.  
       Therefore, it is a natural question to ask why the N-methylthio β-lactam- 
containing nanoparticles have such enhanced antibacterial activities even at very low 
concentrations.  
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              Fig. 3-34 Comparison of antibacterial activities against MRSA 653 
 
       Though the mode of antibacterial action of these nanoparticles is unknown, one 
possible answer is that N-methylthio β-lactam-containing nanoparticles have nano-
size diameters (40–150 nm) and can easily penetrate into the bacteria cell through a 
process called endocytosis, and thus, the bioavailability of the antibiotic can be 
dramatically increased. Fig. 3-33 shows an example of the endocytosis process for a 
polymer drug. To study this proposed mechanism, the relationship between particle 
size and bioactivity, as well as the preparation of fluorescence probe containing 
nanoparticles, are the subject of our current investigations. 
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drug
polymeric 
nanoparticles
adsorption
endocytosis
cell membrane
lysosomal
hydrolysis
release drugs  
Fig. 3-35 Proposed mechanism of drug delivery by endocytosis13   
 
3-10  Conclusions 
       N-Methylthio β-lactam containing nanoparticles were prepared by a novel 
nanoemulsion polymerization technique with ethyl acrylate as a co-monomer. This 
method has advantages over the conventional emulsion polymerization methods 
because a solid co-monomer (β-lactam drug) can be utilized.  
       SEM studies show that the polymeric nanoparticles have a microspherical 
morphology with particle sizes of 40-150 nm, and the 7:1 copolymeric nanoparticles 
have the smallest particle sizes (40-80 nm).  The N-thiolated β-lactam containing 
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nanoparticles display potent anti-MRSA activity at low drug amount compared with 
penicillin G and vancomycin. The strongest bioactivity was observed in the 7:1 (ethyl 
acrylate:lactam) nanoparticles, which correlates with it having the smallest particle 
size (40-80 nm).  Although at this time, the relationship between particle size and 
activity is not clear and the mode of action is unknown, the N-thiolated β-lactam 
containing nanoparticles dramatically enhance bioactivity, possibly due to increased 
bioavailability of the antibiotic via endocytosis. Further examination of this proposed 
mechanism is the subject of our current investigations. 
 
 
3.11 Experimental  
       All reagents were purchased from Sigma-Aldrich Chemical Company and used 
without further purification. Solvents were obtained from Fisher Scientific Company. 
Thin layer chromatography (TLC) was carried out using EM Reagent plates with a 
fluorescence indicator (SiO2-60, F-254). Products were purified by flash 
chromatography using J.T. Baker flash chromatography silica gel (40 µm). NMR 
spectra were recorded in CDCl3 unless otherwise noted. 13C NMR spectra were proton 
broad-band decoupled.  
 
Procedure for the Synthesis of N-(4-Methoxyphenyl)-(2-chlorophenyl)imine (22). 
To a solution of p-anisidine (9.64 g, 78 mmol) in 25 ml of CH2Cl2 was added 2-
chlorobenzaldehyde 21 (10.50 g, 64 mmol) and a catalytic amount of camphor- 
sulfonic acid. The resultant mixture was stirred until TLC indicated the disappearance 
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of starting materials.  The solvent was removed under reduced pressure, and the crude 
material was purified by recrystallization from methanol to yield 15.56 g (89%) of 22 
as a yellow solid. mp 56-57 °C. 1H NMR (250 MHz) δ 8.95 (s, 1H), 8.25 (m, 1H), 
7.43-7.35 (m, 3H), 7.29 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 8.6 Hz, 2H), 3.85 (s, 3H). 13C 
NMR (63 MHz) δ 158.6, 154.6, 144.5, 135.7, 133.4, 131.7, 129.8, 128.3, 127.0, 122.5, 
114.3, 55.4.  
 
Procedure for the Synthesis of 3-Acetoxy-N-(4-methoxyphenyl)-4-(2-chlorophenyl)-
2-azetidinone (23).  
 
To a stirred solution of N-(4-methoxyphenyl)-(2-chlorophenyl)imine 22 (17.00 g, 69.15 
mmol) and triethylamine (26.8 g, 36 ml, 207.6 mmol) was added a solution of 
acetoxyacetyl chloride (9.76 g, 7.69 ml, 90.0 mmol) in methylene chloride (30 ml) 
dropwise over 10 minutes. The resultant mixture was stirred at rt until TLC indicated the 
disappearance of starting material.  The solvent was removed under reduced pressure, 
and the crude material was purified by washing with ice-cold methanol to give 19.48 g 
(86%) of 23 as white solid, mp 130-132 oC. 1H NMR (250 MHz) δ 7.43 (d, J = 7.8 Hz), 
7.29-7.24 (m, 5H), 6.83 (d, J = 8.3 Hz, 2H), 6.16 (d, J = 4.6 Hz, 1H), 5.78 (d, J = 4.6 Hz, 
1H), 3.76 (s, 3H), 1.76 (s, 3H). 13C NMR (63 MHz) δ 168.7, 161.4, 156.7, 133.8, 130.2, 
130.0, 129.8, 128.7, 126.8, 118.6, 114.5, 75.4, 58.2, 55.4, 19.9. 
 
Procedure for the Synthesis of 3-Hydroxy-N-(4-methoxyphenyl)-4-(2-chloro 
phenyl)-2-azetidinone (24).  
 
To a solution of β-lactam 23 (8.00 g, 23.1 mmol) in 50 ml of acetone was added KOH 
(1.30 g, 23.1 mmol) in 20 ml of methanol at 0oC.  The resultant mixture was stirred for 5 
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minutes, and 50 ml of water was added.  The product was precipitated and isolated by 
filtration to yield 6.8 g (96%) of 24 as a white solid, mp 178-180 oC. 1H NMR (250 
MHz) δ 7.48 (d, J = 7.3 Hz, 1H), 7.34-7.24 (m, 5H), 6.85 (d, J = 9.0 Hz, 2H), 5.63 (d, J = 
5.1 Hz, 1H), 5.34 (d, J = 5.1 Hz, 1H), 3.78 (s, 3H), 1.74 (bs, 1H). 13C NMR (63 MHz, 
DMSO-d6), δ 166.6, 156.1, 133.1, 132.9, 131.0, 129.8, 129.6, 128.9, 127.4, 118.6, 115.0, 
77.2, 60.0, 55.7. 
 
 Procedure for the Synthesis of 3-acryloyl-N-(4-methoxyphenyl)-4-(2-chlorophenyl)-
2-azetidinone (25). 
 
 To a solution of C3-hydroxy β-lactam 24 (5.80 g, 19.1 mmol) in 30 ml of freshly 
distilled CH2Cl2 was added NaH (60% suspension in mineral oil, 0.83 g, 21.0 mmol), 
and the mixture was stirred for 15 min at room temperature.  Acryloyl chloride (2.59 g, 
28.64 mmol) was then added dropwise and the resultant mixture was stirred until TLC 
indicated the disappearance of starting material. The reaction was quenched with a 5% 
solution of NH4Cl and extracted (3x20 ml) with CH2Cl2. The combined organic layers 
were dried over anhydrous MgSO4 and purified with column chromatography on silica 
gel (1:4, EtOAc:hexanes) to give 4.92 g (72 %) of 25 as a white solid, mp 99-100 °C. 1H 
NMR (250 MHz) δ 7.33 (d, J = 7.9 Hz, 1H), 7.23-7.10 (m, 5H), 6.75 (d, J = 8.9 Hz, 2H), 
6.17 (d, J = 5.0 Hz, 1H), 5.98 (dd, J = 16.9, 1.00 Hz, 1H), 5.74 (dd, J = 16.9, 10.4 Hz, 
1H), 5.69 (d, J = 5.0 Hz, 1H), 5.59 (d, J = 10.4, 1.0 Hz, 1H), 3.66 (s, 3H).  13C NMR (63 
MHz) δ 163.6, 161.2, 156.6, 133.7, 132.3, 130.3, 130.1, 129.8, 128.5, 126.8, 126.5, 
118.6, 114.4, 75.3, 61.3, 58.2, 55.3. 
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 Procedure for the Synthesis of 3-acryloyl-N-methylthio-4-(2-chlorophenyl)-2-
azetidinone (27). 
 
To a solution of 25 (4.00 g, 11.2 mmol) in 40 ml of CH3CN in an ice-water bath was 
added ceric ammonium nitrate (18.39 g, 33.54 mmol) in 40 ml of water. The resultant 
mixture was stirred for 5 min, and 20 ml of water was added.  The solution was 
extracted (3x5 ml) with EtOAc.  The combined organic layers were washed with 5% 
NaHSO3, 5% NaHCO3, and dried over anhydrous MgSO4. The solvent was removed 
under reduced pressure to yield 2.14 g (76 %) of 26 as a crude brown oil. Without 
futher purification, compound 26 (2.00 g, 8.0 mmol) was dissolved in 30 ml of dry 
CH2Cl2 and N-(methylthio)phthalimide (2.30 g, 11.9 mmol) and 3-5 drops of 
triethylamine were added. The resultant mixture was refluxed for overnight. The 
solvent was removed under reduced pressure to yield a brown solid.  The brown solid 
was redissolved in CH2Cl2, and washed with 1% NaOH. The organic layer was dried 
over anhydrous MgSO4. The solvent was removed under reduced pressure to yield a 
brown semi-solid, which was purified by column chromatography on silica gel with 
gradient elution (1:9 then 1:4 EtOAc:hexanes) to yield 2.00 g (88%) of 27 as a white 
solid. 1H NMR (250 MHz) δ 7.35-7.26 (m, 4H), 6.20 (d, J = 5.1 Hz, 1H), 6.06 (dd, J 
= 16.7, 1.9 Hz, 1H), 5.78 (dd, J = 16.7, 10.4 Hz, 1H), 5.68 (dd, J = 10.4, 1.9 Hz, 1H), 
5.54 (d, J = 10.4 Hz, 1H), 2.51 (s, 3H).  13C NMR (63 MHz) δ 168.3, 163.4, 156.6, 
134.3, 132.6, 129.8, 128.6, 126.6, 126.3, 62.1, 21.9. 
 
Procedure for the synthesis of 2.5:1 (ethyl acrylate:lactam) nanoparticles 
containing N-methylthio β-lactam 
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The mixture of 3-acryloyl N-methylthio β-lactam 27 (500 mg, white solid, mp 92-93 
oC) and ethyl acrylate (440 mg) was warmed to 70 oC with slow stirring under a 
nitrogen atmosphere. Stirring was continued until the mixture was completely mixed 
to give a homogeneous liquid phase. Deionized water (7.94 ml) containing dodecyl 
sulfate, sodium salt (Acros, 15 mg) was added with vigorous stirring and the mixture 
was stirred for one hour to give a milky pre-emulsion state. A solution of potassium 
persulfate (Sigma, 4 mg) dissolved in deionized water ( 0.3 ml) was added under a 
nitrogen atmosphere and the mixture was stirred rapidly at 70 oC for 6 hr. A solution 
of potassium persulfate (1 mg) dissolved in deionized water (0.1 ml) was added to the 
emulsion and rapid stirring was continued for 1hr, to give the N-methylthio β-lactam 
containing nanoparticles as a milky emulsion.  
Other analogs were prepared similarly based on the formulation described in Table 3-
2. 
 
Process for the preparation of samples for SEM 
An aliquot (0.1 ml) of the emulsified suspension of the nanoparticles was diluted 
20,000 to 30,000 times with deionized water (2000 ml- 3000 ml). One drop of the 
diluted emulsion was carefully applied to the surface of a silicon wafer and 
evaporated under a gentle stream of air. The spot of emulsion on the wafer was 
marked with a pen and coated with gold sputter under high vacuum. The gold coated 
nanoparticles were observed by SEM. 
Note: it is really important to keep the silicon wafer clean from any dust. Therefore, 
the best way is to prepare the sample in a clean room.  
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Process for the preparation of thin film on the glass. 
Samples of the nanoparticle emulsions were converted to thin films by coalescence as 
described in section 3.6.1. A rectangular cardboard frame was fixed on glass and the 
emulsion was poured into the frame. The emulsion was left to dry for 48 hours to give 
a transparent thin film.  
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Chapter Four 
 
Preparation of Fluorescence Active Nanoparticles  
 
 
4.1  Introduction 
       Fluorescence has proven to be a versatile tool for numerous applications. This 
powerful technique enables one to study molecular interactions in life science . It is 
promoting the phenomenal sensitivity for the life scientist working on biological analysis. 
But the fluorescence technology offers much more than mere signal-gathering 
capabilities. New developments in instrumentation, software, probes, and applications 
have resulted in a burst of popularity since it was observed over 150 years ago. As the 
theory of fluorescence became better understood, a more powerful set of applications 
emerged and afforded the detailed information about complex molecules and their 
reaction pathways.1,2,3
       The preparation of N-methylthio β-lactam containing fluorescence-active 
nanoparticles are the subject of our current investigations for studying the biological 
mechanism of the nanoparticles. However, there are no reports to prepare fluorescence-
active polymeric nanoparticles. Therefore, it may open a new area in biological 
diagnostics if fluorescence-active nanoparticles are successfully prepared and applied 
appropriately to detection of specific biological molecules, acting as a water dispersed 
biological sensor or biological imaging agent. 
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4.2  Preparation of an Acrylated Fluorescence Monomer  
       The acrylation of fluorescent molecules to serve as free radical acceptors is required 
for microemulsion polymerization. Three compounds were selected for these studies: 
dansyl chloride1 (5-dimethylamino-1-naphthalenesulfonamide, 29), 1-naphthoic acid1 (30) 
and 9-anthracenecarboxylic acid1 (31). They are all fluorescence active. 2-Hydroxy ethyl 
acrylate was used for acrylation of each compound since the terminal hydroxyl group is 
easily coupled with the carboxylic acid group of each substance, and the resultant diester 
linker can be easily hydrolyzed in a biological environment. Dansyl chloride (29) was 
reacted with 2-hydroxyethyl acrylate using amine base, to give compound 32 with 56% 
yield. Both 1-naphthoic acid (30) and 9-anthracenecarboxylic acid (31) was also coupled 
with 2-hydroxy acrylate under EDC/DMAP conditions, to give compound 32 and 33 with 
82% and 21% yield, respectively. The synthesis and 1H NMR spectra are displayed in 
Scheme IV-1 and Fig. 4-1, respectively.  
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         Fig. 4-1 1H NMR spectra of (a) dansyl, (b) naphthyl, and (c) anthracenyl   
acrylates 
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4.3 The Preparation of Fluorescence-Active Polymeric Nanoparticles in an Aqueous 
Emulsion 
 
       The microemulsion polymerization described in section was performed with the 
fluorescent acrylates in an attempt to prepare fluorescence-active nanoparticles.  
       β-Lactam containing fluorescence-active emulsified nanoparticles were successfully 
prepared with C3-acryloyl N-methylthio β-lactam 27, naphthyl acrylate 32 and ethyl 
acrylate at 70 oC. After making a homogeneous solution of these three monomeric 
substances at 70 oC, this mixture was dispersed in aqueous media containing the 
surfactant, sodium lauryl sulfate. Radical polymerization within this pre-formed particle 
mixture  then was performed with an initiator (potassium persulfate) to give the 
nanospherical polymers. Its synthesis and formulation are described in Scheme IV-2 and 
Table IV-1 respectively.  
       Dansyl acrylate 31 could not be used in the emulsion polymerization, because it 
underwent the hydrolysis under the above conditions. 
       The naphthyl containg fluorescence-active emulsified nanoparticles (without the β-
lactam drug) were prepared with naphthyl acrylate 32 and ethyl acrylate in aqueous phase. 
A homogeneous solution of monomeric substances could be made at room temperature 
and this mixture was dispersed in aqueous media with the aid of sodium lauryl sulphate at 
60 oC. Its synthesis and formulation are displayed in Scheme IV-3 and Table IV-2 
respectively. 
       Finally, anthracenyl fluorescence-active emulsified nanoparticles were also prepared 
with anthracenyl acrylate 33, styrene and butyl acrylate in aqueous phase at 70 oC. A 
homogeneous solution of monomeric substances could be made with styrene and butyl 
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acrylate at 70 oC and this mixture was dispersed in aqueous media containing a surfactant, 
sodium lauryl sulfate, to give the anthracenyl fluorescence-active nanoparticles as a 
milky emulsion. However, a homogeneous solution of monomeric substances could not 
be obtained with either ethyl acrylate and butyl acrylate since they could not dissolve the 
anthracenyl acrylate 34 at 70 oC. Its synthesis and the formulation are also displayed in 
Scheme IV-4 and Table IV-3 respectively.  
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Table IV-1 Formulation of Microemulsion Polymerization for 
Fluorescence-Active β-Lactam Copolymeric Nanoparticles
components amount
ethyl acrylate (mg)
β-lactam acrylate (27) (mg)
naphthyl acrylate (33) (mg) 
surfactant1 (mg)
initiator1 (mg)
deionized water (ml)
temperature (oC)
170
100
50
7
1.8
2.0
70
1 surfactant: sodium laury sulfate; initiator: potassium persulfate  
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Table IV-2 Formulation of Microemulsion Polymerization for 
Fluorescence-Active Naphthyl Copolymeric Nanoparticles
components amount
ethyl acrylate (mg)
naphthyl acrylate (33) (mg) 
surfactant1 (mg)
initiator1 (mg)
deionized water (ml)
temperature (oC)
300
100
8
2.0
3.0
60
1 surfactant: sodium laury sulfate; initiator: potassium persulfate  
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Table IV-3 Formulation of Microemulsion Polymerization for 
Fluorescence-Active Anthracenyl Copolymeric Nanoparticles
components amount
butyl acrylate (mg)
styrene (mg)
anthracenyl acrylate (34) (mg) 
surfactant1 (mg)
initiator1 (mg)
deionized water (ml)
temperature (oC)
700
300
10
20
5.0
5.0
70
1 surfactant: sodium laury sulfate; initiator: potassium persulfate  
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4.4  Characterization of Fluorescence Active Emulsified Nanoparticles  
 
4.4.1 Scanning Electron Microscopy (SEM) 
       The morphology and the size of the emulsified particles were examined by Scanning 
Electron Microscopy (SEM). The sample of nanoparticles was prepared on a silicon 
wafer by evaporation of water under a gentle stream of air, and then coated with gold 
sputter under high vaccum. The gold-coated nanoparticles were then observed by SEM. 
       The SEM images of β-lactam, naphthyl, and anthracenyl fluorescence-active 
nanoparticles are displayed in Fig. 4-2, 4-3, and 4-4 respectively. The images of 
nanoparticles show that the particles have microspherical morphology and a particle size 
distribution of about 30-120 nm.  Fig. 4-2 and 4-4 also show that some of particles are 
fused by the coalescence due to not enough dilution of the samples when they are 
prepared.  
                                                                                                                           
                         
                       Fig. 4-2 SEM image for β-lactam fluorescence-active  
  emulsified nanoparticles with particles size (60-120 nm) 
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                       Fig. 4-3 SEM image for naphthalyl fluorescence-active 
                       emulsified nanoparticles with particle size (30-60 nm) 
 
 
      
  Fig. 4-4 SEM image for anthracenyl fluorescence-active 
                          emulsified nanoparticles with particle size (60-120 nm) 
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4.4.2 1H NMR Spectra Analysis 
       1H NMR Spectroscopy is a very useful tool to analyze the chemical structure of 
organic molecules. It can also be used to determine the mole ratio of each of the 
monomeric units, in copolymers. Fig. 4-5 shows 1H NMR spectra for the dry films 
obtained by coalescing the nanoparticle emulsions of naphthyl (a), β-lactam (b), and 
anthracenyl (c) copolymer. The olefin protons of the acrylate moiety in the range of 5.6-
6.1 ppm do not appear in the spectrum, indicating that all acrylic monomers participated 
in polymerization. In addition, each monomer composition in the polymer was 
determined by the peak integration in the 1H NMR spectrum. For instance, the 
comparison of the peak integration for C3 or C4 proton of β-lactam, methylene protons of 
ethyl acrylate, and one of aromatic protons in naphthyl group in (b) spectra gave the mole 
ratio of each monomer in the copolymer. 
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Fig. 4-5 1H NMR spectra for (a) naphthyl, (b) β-lactam  and (c) anthracenyl 
fluorescence-active copolymer 
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4.5 Discussion 
       Fluorescence-active emulsified nanoparticles were successfully prepared by a novel 
microemulsion polymerization described in chapter three. The fluorescence-active 
nanoparticles were made for the first time and may open opportunities to construct new 
biological diagnostic systems to detect a certain microbe, cell, or biomolecule. This will 
require further development. 
       Acrylation with naphthyl carboxylic acid 30 and anthracenyl carboxylic acid 31 was 
performed with 2-hydroxy ethyl acrylate using EDC/DMAP condition to give acrylated 
compound 33 and 34 which are all fluorescence-active.  
       The β-lactam containing fluorescence active emulsified nanoparticles were prepared 
with the monomer combination of C3-acryloyl N-methylthio β-lactam 27, naphthalyl 
acrylate 33, and ethyl acrylate. The homogeneous solution of monomeric substances was 
formed at 70 oC, followed by dispersion in water phase with aid of surfactants. The mole 
ratio of each monomer in the polymer is 1 : 4.5 : 0.6, and the particle size distribution is 
approximately 60-120 nm. These nanoparticles were prepared for possible use in 
identifying the mechanism, of how the drug enters the cell of MRSA (chapter 3).  
       The fluorescence-active polymeric nanoparticles without drug are also expected to be 
very important materials as leads to bio-diagnostics because of easy and fast detection of 
the fluorescence probe. First, naphthyl-contaning fluorescence-active emulsified 
nanoparticles were prepared with ethyl acrylate as a co-monomer using microemulsion 
polymerization. A water-insoluble high viscous oil, naphthyl acrylate 33, was pre-mixed 
with ethyl acrylate at room temperature to give a homogeneous liquid. Following this, 
emulsion polymerization was performed at 60 oC to give naphthyl fluorescence-active 
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emulsified nanoparticles as a milky emulsion. The mole ratio of ethyl acrylate and 
naphthyl acrylate in the polymer is 8:1 and the particle size distribution is approximately 
30-60 nm. 
       Anthracenyl fluorescence-active emulsified nanoparticles which have a different 
fluorescent emission were also prepared with butyl acrylate and styrene as co-monomers 
using microemulsion polymerization. The mole ratio of each monomer was not 
determined with 1H NMR spectra analysis since the peak integration of anthracenyl group 
is too small to detect. The particle size distribution is approximately 60-120 nm. Even 
though the emulsion polymerization was attempted with the monomer combination of 
ethyl acrylate-anthracenyl acrylate and the butyl acrylate-anthracenyl acrylate 
respectively, the anthracenyl emulsified nanoparticles were not prepared since neither 
monomer combinations could form a homogeneous liquid phase at 70 oC. Thus, these 
experiments failed. 
        The fluorescent emission colors for a naphthyl and an anthracenyl emulsions and 
their corresponding thin films formed by coalescence were compared with non 
fluorescent β-lactam emulsion and its thin film upon UV irradiation. The image (a) and 
(a’) in Fig. 4-6 displays the fluorescent emission colors for the non fluorescent β-lactam 
nanoparticles as well as that of naphthyl, and anthracenyl system upon UV irradiation. 
The non-fluorescent β-lactam emulsion shows no color change while both the naphthyl 
and anthracenyl nanoparticle emulsions emit a blue and a bright blue-green fluorescent 
color respectively. The image (b) and (b’) in Fig. 4-6 also displays the fluorescent 
emission colors for the thin films of corresponding samples upon UV irradiation. Each 
sample shows the same fluorescent emission colors as in the emulsion. Therefore, 
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naththyl and anthracenyl emulsified nanoparticles and their corresponding thin films are 
all fluorescence-active and emit a blue and a bright blue-green fluorescent color 
respectively. 
       As an on-going study, the naphthyl and anthracenyl copolymeric emulsified 
nanoparticles are going to be prepared by using microemulsion polymerization. If the 
copolymeric nanoparticles emit the totally different color in fluorescent emission, that 
means new fluorescence-active nanoparticles can be created with simple microemulsion 
copolymerization of two different fluorescent probes. Therefore, this research can 
potentially bring significant advantages and applications in the bio-diagnostics area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (a)                     UV Lamp Off                        (b)                UV Lamp Off       
         
 
(a’)                   UV Lamp On                          (b’)            UV Lamp On        
       
β-lactam naphthyl anthracenyl
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 β-lactam naphthyl anthracenyl
 
Fig. 4-6  Comparison of the non fluorescence-active β-lactam and the fluorescence-
active naphthalyl and anthracenyl emulsified nanoparticles and their corresponding 
thin films upon UV Irradiation 
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4.6  Experimental  
All reagents were purchased from Sigma-Aldrich Chemical Company and used without 
further purification. Solvents were obtained from Fisher Scientific Company. Thin layer 
chromatography (TLC) was carried out using EM Reagent plates with a fluorescence 
indicator (SiO2-60, F-254). Products were purified by flash chromatography using J.T. 
Baker flash chromatography silica gel (40 µm). NMR spectra were recorded in CDCl3 
unless otherwise noted. 13C NMR spectra were proton broad-band decoupled.  
 
Procedure for the synthesis of 2-(5-dimethylamino-naphthalene-1-sulfonyloxy)-ethyl 
acrylate (32). 
 
To a solution of 2-hydroxyethyl acrylate 28 (25.8 mg, 0.2 mmol) in 2 ml of freshly 
distilled CH2Cl2 was added diisopropylethylamine (DIPEA, 0.35 ml, 0.2 mmol) dropwise 
at 0oC. Dansyl chloride (50.0 mg, 0.19 mmol) was then added dropwise and the resultant 
mixture was stirred at room temperature until TLC indicated the disappearance of starting 
material. The reaction was quenched with a 5% solution of NH4Cl and extracted (3x20 
ml) with CH2Cl2. The combined organic layers were dried over anhydrous MgSO4 and 
purified with column chromatography on silica gel (1:4, EtOAc:hexanes) to give 37.5 mg 
(56 %) of 32 as a yellow semi solid. 1H NMR (250 MHz) δ 8.61 (d, J = 8.6 Hz, 1H), 8.26 
(t, J = 6.3 Hz, 2H), 7.56 (m, 2H), 7.20 (d, J = 7.7 Hz, 1H), 6.19 (dd, J = 16.5, 2.5 Hz, 1H), 
5.80 (dd, J = 16.5, 10.3 Hz, 1H), 5.71 (dd, J = 16.5, 10.3 Hz, 1H), 4.25 (m, 4H), 2.88 (s, 
6H).  13C NMR (63 MHz) δ 158.0, 151.7, 131.8, 131.5, 130.9, 130.6, 129.8, 128.8, 127.3, 
123.0, 119.4, 115.6, 67.8, 61.5, 45.4. 
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Procedure for the synthesis of naphthalene-1-carbonyloxy-2-ethyl acrylate (33). 
To a solution of 2-hydroxyethyl acrylate 28 (1.01 g, 8.7 mmol) and 1-naphthoic acid 30 
(1.00 g, 5.8 mmol) in 10 ml of freshly distilled CH2Cl2 was added EDC (1.60 g, 8.7 
mmol) and DMAP (cat. amount) at room temperature. The resultant mixture was stirred 
at room temperature until TLC indicated the disappearance of starting material. The 
reaction was quenched with a 5% solution of NH4Cl and the mixture was washed with 
water. After extraction with EtOAc (3x20 ml), the organic layers were dried over 
anhydrous MgSO4 and purified with column chromatography on silica gel (1:4, 
EtOAc:hexanes) to give 1.29 g (82 %) of 33 as a colorless oil. 1H NMR (250 MHz) δ 
8.91 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 7.1 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 
8.0 Hz, 1H), 7.57 (m, 3H), 6.49 (d, J = 17.3 Hz, 1H), 6.19 (dd, J = 17.3, 10.4 Hz, 1H), 
5.71 (d, J = 10.4 Hz, 1H), 4.66 (m, 2H), 4.58 (m, 2H).  13C NMR (63 MHz) δ 167.2, 
165.9, 133.8, 133.6, 131.5, 131.3, 130.5, 128.6, 128.0, 127.8, 126.6, 126.2, 125.7, 124.5, 
62.7, 62.3.  
 
Procedure for the synthesis of anthracene-9-carbonyloxy-2-ethyl acrylate (34). 
To a solution of 2-hydroxyethyl acrylate 28 (0.78 g, 6.8 mmol) and 1-naphthoic acid 30 
(1.00 g, 5.8 mmol) in 10 ml of freshly distilled CH2Cl2 was added EDC (0.86 g, 4.5 
mmol) and DMAP (cat. amount) at room temperature. The resultant mixture was stirred 
at room temperature until TLC indicated the disappearance of starting material. The 
reaction was quenched with a 5% solution of NH4Cl and the mixture was washed with 
water. After extraction with EtOAc (3x20 ml), the organic layers were dried over 
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anhydrous MgSO4 and purified with column chromatography on silica gel (1:4, 
EtOAc:hexanes) to give 0.30 g (21 %) of 34 as a yellow solid, mp 66-68 oC. 1H NMR 
(250 MHz) δ 8.54 (s, 1H), 8.06 (dd, J =  14.7, 8.0 Hz, 4H), 7.52 (m, 4H), 6.21 (d, J = 17.2 
Hz, 1H), 6.21 (dd, J = 17.2, 10.5 Hz, 1H), 5.91 (d, J = 10.5 Hz, 1H), 4.89 (m, 2H), 4.62 
(m, 2H).  13C NMR (63 MHz) δ 169.3, 165.3, 131.7, 130.9, 129.7, 128.7, 127.9, 127.1, 
125.5, 124.9, 63.2, 62.3. 
 
Procedure for the synthesis of fluorescence-active emulsified nanoparticles.  
 
The mixture of 3-acryloyl N-methylthio β-lactam 27 (100 mg, white solid, mp 92-93 oC), 
naphthyl acrylate 33 (50 mg), and ethyl acrylate (170 mg) was warmed to 70 oC with 
slow stirring under a nitrogen atmosphere. Stirring was continued until the mixture was 
completely mixed to give a homogeneous liquid phase. Deionized water (1.7 ml) 
containing dodecyl sulfate, sodium salt (Acros, 7 mg) was added with vigorous stirring 
and the mixture was stirred for one hour to give a milky pre-emulsion state. A solution of 
potassium persulfate (Sigma, 1.8 mg) dissolved in deionized water ( 0.3 ml) was added 
under a nitrogen atmosphere and the mixture was stirred rapidly at 70 oC for 6 hr. A 
solution of potassium persulfate (0.5 mg) dissolved in deionized water (0.1 ml) was 
added to the emulsion and rapid stirring was continued for 1hr, to give the N-methylthio 
β-lactam containing fluorescence-active emulsified nanoparticles as a milky emulsion.  
Other analogs were prepared similarly based on the formulation described in Table IV-2 
and Table IV-3 respectively. 
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Process for the preparation of thin film on the glass. 
Samples of the nanoparticle emulsions were converted to thin films by coalescence as 
described in previous chapter. A rectangular cardboard frame was fixed on glass and the 
emulsion was poured into the frame. The emulsion was left to dry for 48 hours to give a 
transparent thin film.  
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Chapter Five 
 
Conclusions and Future Directions 
 
       Methicillin-resistant Staphylococcus Aureus (MRSA) is now the most challenging 
bacterial pathogen affecting patients in hospitals and in care centers. Infections caused by 
this bacterium has become a serious national and global problem. The need to develop 
new drugs for MRSA is the force driving this research project. 
       N-Thiolated β-lactams are a new family of potent antibacterial compounds that 
selectively inhibit the growth of Staphylococcus species including methicillin-resistant 
Staphylococcus aureus (MRSA), over other common bacterial genera. Recent efforts 
within this laboratory have been on understanding possible structure-activity profiles of 
this previously unstudied family of antibiotics. 
       In chapter 2 of this thesis, results were discussed on the effect of a fatty ester group 
(CO2R) on the C4-phenyl ring of N-methylthio β-lactams. The initial expectation was that 
attachment of long chain ester moieties might increase the hydrophobicity, and thus 
enhance the drug’s ability to penetrate through the cell membrane. However, the result 
indicate that there is an optimal chain length for the fatty ester groups, with antibacterial 
activity dropping off rapidly when more than seven carbon atoms are in the chain. These 
results led to the idea about examining a β-lactam conjugated polymer as a possible drug 
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delivery method, with the polymer essentially serving as a surrogate for an extremely 
large, lipophilic ester side chain on the lactam ring. The question being asked is whether 
this would enhance, or destroy, biological activity.  
       To synthesize the initial drug-polymer candidate, microemulsion polymerization of 
an acrylate-substituted lactam was done in aqueous solution to form hydrophilic 
polymeric nanoparticles containing the highly water-insoluble solid antibiotic, N-
methylthio β-lactam. This method has advantages over the conventional emulsion 
polymerization methods because a solid co-monomer (β-lactam drug) can be utilized. 
       SEM studies show that these polymeric nanoparticles have a microspherical 
morphology with nano-sizes of 40-150 nm. The N-thiolated β-lactam containing 
nanoparticles display potent anti-MRSA activity at much lower drug amounts compared 
with free lactam drug, penicillin G or vancomycin. Although at this time the relationship 
between particle size and activity is not clear and the mode of action is unknown, the N-
thiolated β-lactam containing nanoparticles dramatically enhance bioactivity, possibly 
due to increased bioavailability of the antibiotic via endocytosis.  
       Therefore, the preparation and the biological testing of N-thiolated β-lactam 
containing nanoparticles of different particle size distributions have to be performed to 
ascertain the relationship between particle size and activity. In vivo and cytotoxicity 
testing are also necessary for further progress towards commercialization. 
       Fluorescence-active emulsified nanoparticles containing naphthyl or anthracenyl side 
chains were also successfully prepared by microemulsion polymerization for possible use 
in fluorescence studies to determine if the drug enters the cell of MRSA through 
endocytosis.        
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       It will be necessary to further develop these and possibly other related fluorescence-
active emulsified nanoparticles into more intelligent forms which are able to selectively 
bind to certain biological targets. The emulsified nanoparticles can be converted to dry 
films that are readily soluble in organic solvents, but which do not retain biological 
activity. Future work in this laboratory is likely to focus on development of drug-
containing thin film polymers for a variety of biomedical and research related 
applications.  
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